Prof. TANER DEMİRER

Publication Network

Articles 197

1. CT-1425: Higher Pretransplant Lymphocyte Count Is Associated With Improved Survival in Allogeneic Stem Cell Transplantation With Antithymocyte Globulin

Kökcü G., Dalva K., Yüksel M., Toprak S. K., Topçuoğlu P., Arslan Ö., et al.

Clinical Lymphoma Myeloma and Leukemia , vol.25, pp.1065, 2025 (Peer-Reviewed Journal)

2. Akut Miyeloid Lösemi Tanılı Fit Yaşlı Hastalarda Allojeneik Hematopoetik Kök Hücre Nakli: Tek Merkez Deneyimi

SÖNMEZ G. M., YAVUZ G., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , vol.9, 2025 (TRDizin)

3. Periferik T-Hücreli Lenfoma Hastalarının Geriye Dönük Değerlendirmesi: Tek Merkez Gerçek Yaşam Deneyimi

YÜKSEL M., . C. K. D., CENGİZ SEVAL G., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , vol.9, 2025 (TRDizin)

4.

KOYUN D., ATEŞAĞAOĞLU B., YÜKSEL S., SEVAL G. C., BOZDAĞ S. C., TOPRAK S. K., et al.

Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , vol.8, no.3, pp.86-91, 2024 (TRDizin)

5. Anaplastic Multiple Myeloma: An Aggressive Myeloma Variant with A Poor Response to Autologous Stem Cell Transplantation

Koyun D., Doğan İ. Ö., Kuzu I., Toprak S. K., Özcan M., Demirer T.

Ankara Üniversitesi Tıp Fakültesi Mecmuası , vol.77, no.4, pp.416-418, 2024 (Peer-Reviewed Journal)

6. Allogeneic Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis: A 20-year Experience in a Single Center

CENGİZ SEVAL G., Civriz Bozdag S., TOPRAK S. K., Kurt Yuksel M., TOPÇUOĞLU P., ARSLAN Ö., et al.

Balkan medical journal , vol.40, no.3, pp.197-204, 2023 (SCI-Expanded, Scopus)

7. Eltrombopag for the Treatment of Poor Graft Function Following Haematopoietic Cell Transplantation: Real-Life Data

Kırcalı E., Cengiz Seval G., Öztürk C., Yılmaz H., Koyun D., Civriz Bozdağ S., et al.

BALKAN MEDICAL JOURNAL , vol.40, no.1, pp.51-56, 2023 (SCI-Expanded, Scopus)

8. Pretransplant Consolidation Therapies Improve the Outcome of Myeloablative Allogeneic Transplantation in Adults with Ph-negative Acute Lymphoblastic Leukemia

Ozdemir Z. N., Kircali E., Şahin U., Seval G., Bozdağ S. C., Toprak S. K., et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.22, no.8, pp.596-600, 2022 (SCI-Expanded, Scopus) Sustainable Development

9. Alpha-1-Antitrypsin Experience for Steroid-Resistant Acute Graft-Versus-Host Disease

KOYUN D., CENGİZ SEVAL G., Kircali E., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., et al.

INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION , vol.38, no.3, pp.601-605, 2022 (SCI-Expanded, Scopus)

10. The efficacy and safety of second allogeneic hematopoietic stem cell transplantation.

Toprak S. K., Korcalo E., Seval G. C., Bozdag S. C., Yuksel M. K., Topcuoglu P., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.40, no.16, 2022 (SCI-Expanded, Scopus)

11. İkinci Allojenik Kök Hücre Nakli: Gerçek Yaşam Verisi

KIRCALI E., CENGİZ SEVAL G., ÖZTÜRK C., YILMAZ H., ŞENOYMAK M. C., YAVUZ G., et al.

Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , vol.6, no.2, pp.50-55, 2022 (TRDizin)

12. The Outcome of Autologous Hematopoietic Cell Transplantation in Elderly Patients with Aggressive Non-Hodgkin Lymphoma

Ilhan O., Cengiz Seval G., Civriz Bozdag S., Toprak S. K., Kurt Yuksel M., Topcuoglu P., et al.

BLOOD , vol.138, 2021 (SCI-Expanded, Scopus)

13. Relaps Refrakter Hodgkin Lenfomada Brentuksimab Vedotin Kullanımı: Tek Merkez Deneyimi

Koyun D., Cengiz Seval G., Sökmen M., Akkuş E., Atilla E., Civriz Bozdağ S., et al.

Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , vol.5, no.1, pp.1-4, 2021 (TRDizin)

14. Prospective Follow-up of Panel Reactive Antibodies From Diagnosis Until Completion of Therapy Including Allogeneic Stem Cell Transplantation Among Patients With Acute Leukemia.

Sahin Eroglu D., Dalva K., Kalaci E., Toprak S. K., Civriz Bozdag S., Topcuoglu P., et al.

Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation , 2021 (SCI-Expanded, Scopus)

15. Comparative Analysis and Validation of CIBMTR Early Relapse Risk Score with ISS and R-ISS: Single Center Experience from Ankara University

Seval G. C., Bozdag S. C., Toprak S. K., Yuksel M. K., Topcuoglu P., Arslan O., et al.

Transplantation and Cellular Therapy , vol.27, no.3, pp.401, 2021 (Scopus)

16. Impact of Peritransplant Metronidazole Use on Acute Graft Versus Host Disease in Allogeneic Hematopoietic Transplant Patients

Kircali E., Seval G. C., Bozdag S. C., Yuksel M. K., Topcuoglu P., Arslan O., et al.

Transplantation and Cellular Therapy , vol.27, no.3, pp.271, 2021 (Scopus)

17. Treatment approaches for managing patients with hematological malignancies in the time of COVID-19 pandemic

CENGİZ SEVAL G., TOPÇUOĞLU P., DEMİRER T.

TURKISH JOURNAL OF MEDICAL SCIENCES , vol.51, no.6, pp.2799-2809, 2021 (SCI-Expanded, Scopus, TRDizin)

18. The Efficacy of Therapeutic Thrombocytapheresis in Patients with Thrombocytosis

NARLI ÖZDEMİR Z., ŞAHİN U., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., et al.

Ankara Üniversitesi Tıp Fakültesi Mecmuası , vol.74, 2021 (TRDizin)

19. Role of Chimerism and flow-cytometric Monitoring of Measurable Residual Disease(MRD) after Allogeneic Hematopoietic Stem Cell Transplantation(Allo-HSCT) in Predicting Relapse in Acute Myeloid Leukemia(AML)

CENGİZ SEVAL G., Ulas E. B., TOPRAK S. K., CİVRİZ BOZDAĞ S., Yuksel M. K., TOPÇUOĞLU P., et al.

BONE MARROW TRANSPLANTATION , vol.55, no.SUPPL 1, pp.192-193, 2020 (SCI-Expanded, Scopus)

20. The Influence of anti-thymocyte Globulin(ATG) on the Outcomes of Patients with AML W/wo Measurable Residual Disease(MRD) at the time of Unrelated Donor Transplantation

CENGİZ SEVAL G., Kircali E., BALTACI M. A., CİVRİZ BOZDAĞ S., Yuksel M. K., TOPÇUOĞLU P., et al.

BONE MARROW TRANSPLANTATION , vol.55, no.SUPPL 1, pp.204, 2020 (SCI-Expanded, Scopus)

21. Treatment of Thrombocytopenia after Allogeneic Stem Cell Transplantation with Eltrombopag

Kircali E., CENGİZ SEVAL G., KOYUN D., Ozturk C., Uslu A., CİVRİZ BOZDAĞ S., et al.

BONE MARROW TRANSPLANTATION , vol.55, no.SUPPL 1, pp.410-411, 2020 (SCI-Expanded, Scopus)

22. Flamsa-based High-dose Sequential Conditioning Regimen followed by Allogeneic Hematopoietic Stem Cell Transplantation(ALLO-HSCT): Is It Effective in Patients with Primary Refractory or Relapsed Acute Leukemia?

CENGİZ SEVAL G., Kircali E., CİVRİZ BOZDAĞ S., TOPRAK S. K., Yuksel M. K., ARSLAN Ö., et al.

BONE MARROW TRANSPLANTATION , vol.55, no.SUPPL 1, pp.305-306, 2020 (SCI-Expanded, Scopus)

23. Bir Nakil Merkezinin 11 YıllıkAllojeneik Kök Hücre Nakli Deneyimi

Kırcalı E., SEVAL G. C., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

LLM Dergi , vol.4, no.3, pp.50-54, 2020 (TRDizin)

24. Thyroid dysfunctions in adult patients after allogeneic hematopoietic stem cell transplantation

Atilla P. A., AKKUŞ E., Atilla E., Gökmen İnan N., CİVRİZ BOZDAĞ S., Yuksel M. K., et al.

CLINICAL TRANSPLANTATION , vol.34, no.10, 2020 (SCI-Expanded, Scopus)

25. Effects of ABO incompatibility in allogeneic hematopoietic stem cell transplantation

Atilla P. A., Akkus E., Atilla E., Gokmen N., Bozdag S. C., TOPRAK S. K., et al.

TRANSFUSION CLINIQUE ET BIOLOGIQUE , vol.27, no.3, pp.115-121, 2020 (SCI-Expanded, Scopus)

26. Our Approach in Allogeneic Stem CellTransplantation: 11 Years of Experience

Kırcalı E., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , vol.4, no.3, pp.50-54, 2020 (TRDizin)

27. Our Treatment Approach to Hairy Cell Leukemia

ATACA ATİLLA P., ATİLLA E., KIRCALI E., TOPÇUOĞLU P., DEMİRER T., ARSLAN Ö., et al.

Ankara Üniversitesi Tıp Fakültesi Mecmuası , vol.73, no.1, pp.5-8, 2020 (TRDizin)

28. Allogeneic hematopoietic stem cell transplantation for primary myelofibrosis: A single-center experience.

Demirer T., Cengiz Seval G., Civriz Bozdag S., Toprak S. K., Kurt Yuksel M., Topcuoglu P., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.38, no.15_suppl, pp.19522, 2020 (SCI-Expanded, Scopus)

29. Tüylü Hücreli Lösemide Tedavi Yaklaşımımız

ATACA ATİLLA P., ATİLLA E., Kırcalı E., TOPÇUOĞLU P., DEMİRER T., ARSLAN Ö., et al.

Ankara Üniversitesi Tıp Fakültesi Mecmuası , vol.73, no.1, pp.5-8, 2020 (TRDizin)

30. Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis

Seval G. C., Ozturk N., Bozdag S. C., Yuksel M. K., Topcuoglu P., Arslan O., et al.

Transplantation and Cellular Therapy , vol.26, no.3, pp.109-110, 2020 (SCI-Expanded)

31. Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data

Seval G. C., Uslu A., Kircali E., Bozdag S. C., Toprak S. K., Yuksel M. K., et al.

Transplantation and Cellular Therapy , vol.26, no.3, pp.305-306, 2020 (SCI-Expanded)

32. An uncommon presentation of diffuse large B cell lymphoma with multiple peripheral nerve involvement demonstrated BY 18F-FDG PET/CT

Araz M., Soydal Ç., Ozturk C., Özkan E., Demirer T.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING , vol.47, no.1, pp.218-219, 2020 (SCI-Expanded, Scopus)

33. Graft-versus-cancereffect and innovative approaches in the treatment of refractory solid tumors

Sahin U., DEMİRER T.

TURKISH JOURNAL OF MEDICAL SCIENCES , vol.50, pp.1697-1706, 2020 (SCI-Expanded, Scopus, TRDizin)

34. Impact of Hepatitis B Core Antibody Seropositivity on the Liver Function Tests After Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma

Cengiz Seval G., Karaman Z., Civriz Bozdağ S., Yüksel M., Topçuoğlu P., Arslan Ö., et al.

Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , vol.3, no.3, pp.55-59, 2019 (TRDizin)

35. Negative Impact of High LDH at Diagnosis on OS, But Not PFS, Can Be Overcome by Autologous Stem Cell Transplantation

CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.19, no.10, 2019 (SCI-Expanded, Scopus)

36. Pretransplant hemoglobin and serum creatinine levels correlate with progression free survival in myeloma patients undergoing autologous stem cell transplantation.

Demirer T., Cengiz Seval G., Toprak S. K., Civriz Bozdag S., Yuksel M. K., Topcuoglu P., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.37, no.15_suppl, pp.19532, 2019 (SCI-Expanded, Scopus)

37. Can autologous stem cell transplantation abrogate the poor prognosis associated with high LDH in myeloma patients?

Ilhan O., Cengiz Seval G., Toprak S. K., Civriz Bozdag S., Yuksel M. K., Topcuoglu P., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.37, no.15_suppl, pp.19524, 2019 (SCI-Expanded, Scopus)

38. Impact of ABO Mismatch on Outcomes of Allogeneic Hematopoietic Stem Cell Recipients: 30 Years of Experience with 1016 Patients

Atilla E., Topcuoglu P., Akkus E., Atilla P. A., Bozdag S. C., Yuksel M. K., et al.

Transplantation and Cellular Therapy , vol.25, no.3, pp.322, 2019 (SCI-Expanded)

39. Influence of Conditioning Regimens with Total Body Irradiation (TBI) on Graft Versus Host Disease and Graft Versus Leukemia Effect Following Donor Lymphocyte Infusions (DLI)

Seval G. C., Atilla E., Ulas B., Bozdag S. C., Toprak S. K., Yuksel M. K., et al.

Transplantation and Cellular Therapy , vol.25, no.3, pp.176-177, 2019 (SCI-Expanded)

40. Current approach to early gastrointestinal and liver complications of hematopoietic stem cell transplantation

Atilla E., Atilla P. A., CENGİZ SEVAL G., Bektas M., DEMİRER T.

TURKISH JOURNAL OF GASTROENTEROLOGY , vol.30, no.2, pp.122-131, 2019 (SCI-Expanded, Scopus, TRDizin)

41. The Impact of Pre-transplant Serum Ferritin on Outcomes of Allogeneic Transplantation for Acute Leukemia

ŞAHİN U., ERDAL H., GÜNDÜZ M., MERTER M., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., et al.

Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , vol.3, no.1, pp.9-13, 2019 (Peer-Reviewed Journal)

42. Contemporary patient-tailored treatment strategies against high risk and relapsed or refractory multiple myeloma

Uckun F. M., Qazi S., DEMİRER T., Champlin R. E.

EBIOMEDICINE , vol.39, pp.612-620, 2019 (SCI-Expanded, Scopus)

43. Akut Lösemide Allojeneik Nakil Öncesi Serum Ferritin Düzeyinin Nakil Sonuçlarına Etkisi

ŞAHİN U., HASAN E., GÜNDÜZ M., MERTER M., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., et al.

Lösemi Lenfoma Miyelom Hastaları ve Araştırma Eğitimi Birliği Dergisi , vol.3, no.1, pp.1-3, 2019 (TRDizin)

44. Comparision of Outcomes According to HLA Disparity in Acute Leukemia Patients: A Single Center Institution Experience

Topcuoglu P., Cengiz Seval G., Civriz Bozdag S., Toprak S. K., Kurt Yuksel M., Dalva K., et al.

BLOOD , vol.132, no.Supplement 1, pp.5776, 2018 (SCI-Expanded, Scopus)

45. Clinical Reflection of Immunophenotyping in Paroxysmal Nocturnal Hemoglobinuria: Experience af a Single Center

ŞAHİN U., MERTER M., NARLI ÖZDEMİR Z., DALVA K., CİVRİZ BOZDAĞ S., YÜKSEL M., et al.

Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , vol.2, no.4, pp.93-97, 2018 (TRDizin)

46. Is there a role of high dose chemotherapy and autologous stem cell transplantation in the treatment of Ewing's sarcoma and osteosarcomas?

Karadurmus N., Sahin U., Basgoz B. B., DEMİRER T.

JOURNAL OF BUON , vol.23, no.5, pp.1235-1241, 2018 (SCI-Expanded, Scopus)

47. Primer Mediastinal Büyük BHücreli Lenfoma HastalarımızınTedavi Sonuçlarının Geriye DönükDeğerlendirilmesi

ATİLLA E., ATACA ATİLLA P., Cengiz Seval G., TOPRAK S. K., İLHAN O., ARSLAN Ö., et al.

Türkiye’de Lösemi Lenfoma Miyelom Araştırmaları , vol.2, no.3, pp.60-64, 2018 (TRDizin)

48. Current strategies for the management of autologous peripheral blood stem cell mobilization failures in patients with multiple myeloma

Sahin U., DEMİRER T.

JOURNAL OF CLINICAL APHERESIS , vol.33, no.3, pp.357-370, 2018 (SCI-Expanded, Scopus)

49. Retrospective analysis of 115 unselected patients with mantle cell lymphoma: Single center experience.

CENGİZ SEVAL G., Bulat B., Ozel F., Tasci O., KUZU I., CİVRİZ BOZDAĞ S., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.36, no.15, 2018 (SCI-Expanded, Scopus)

50. Age is Not an Important Factor for Autologous Peripheral Hematopoietic Stem Cell Mobilization and Collection in Patients with Multiple Myeloma

Ilhan O., Seval G. C., Toprak S. K., Bozdag S. C., Yuksel M. K., Topcuoglu P., et al.

Transplantation and Cellular Therapy , vol.24, no.3, pp.142, 2018 (SCI-Expanded)

51. Treatment with methotrexate, rituximab, and cytosine arabinoside followed by autologous stem cell transplantation in primary central nervous system lymphoma: A single-center experience.

Atilla P. A., Atilla E., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., et al.

Hematology/oncology and stem cell therapy , vol.11, no.1, pp.13-17, 2018 (Scopus)

52. Current Approach to Non-Infectious Pulmonary Complications of Hematopoietic Stem Cell Transplantation

CENGİZ SEVAL G., TOPÇUOĞLU P., DEMİRER T.

BALKAN MEDICAL JOURNAL , vol.35, no.2, pp.131-140, 2018 (SCI-Expanded, Scopus, TRDizin)

53. Treatment with methotrexate, rituximab, and cytosine arabinoside followed by autologous stem cell transplantation in primary central nervous system lymphoma: A single-center experiencea

ATACA ATİLLA P., ATİLLA E., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., et al.

Hematology Oncology and Stem Cell Therapy , vol.11, no.1, pp.13-17, 2018 (Scopus)

54. Adult Stem Cells and Medicine

CİVRİZ BOZDAĞ S., YÜKSEL M., DEMİRER T.

CELL BIOLOGY AND TRANSLATIONAL MEDICINE, VOL 1: STEM CELLS IN REGENERATIVE MEDICINE: ADVANCES AND CHALLENGES , vol.1079, pp.17-36, 2018 (SCI-Expanded)

55. Is cytomegalovirus a risk factor for haemorrhagic cystitis in allogeneic haematopoietic stem cell transplantation recipients?

Atilla E., Yalciner M., Ailla P. A., Ates C., CİVRİZ BOZDAĞ S., YÜKSEL M., et al.

ANTIVIRAL THERAPY , vol.23, no.8, pp.647-653, 2018 (SCI-Expanded, Scopus)

56. A review of allogeneic hematopoietic stem cell transplantation in metastatic breast cancer

Karadurmus N., Sahin U., Basgoz B. B., Arpaci F., DEMİRER T.

International Journal of Hematology-Oncology and Stem Cell Research , vol.12, no.2, pp.111-116, 2018 (Scopus) Sustainable Development

57. Extracorporeal photochemotherapy in mycosis fungoides

Atilla E., Atilla P. A., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., Topcuoglu P., et al.

TRANSFUSION CLINIQUE ET BIOLOGIQUE , vol.24, no.4, pp.454-457, 2017 (SCI-Expanded, Scopus)

58. A review of late complications of allogeneic hematopoietic stem cell transplantations

Atilla E., Atilla P. A., TOPRAK S. K., DEMİRER T.

CLINICAL TRANSPLANTATION , vol.31, no.10, 2017 (SCI-Expanded, Scopus)

59. A review of infectious complications after haploidentical hematopoietic stem cell transplantations

Atilla E., Atilla P. A., CİVRİZ BOZDAĞ S., DEMİRER T.

INFECTION , vol.45, no.4, pp.403-411, 2017 (SCI-Expanded, Scopus)

60. Subsequent malignancies after allogeneic hematopoietic stem cell transplantation

Gunduz M., Ozen M., Sahin U., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., et al.

CLINICAL TRANSPLANTATION , vol.31, no.7, 2017 (SCI-Expanded, Scopus)

61. How to manage poor mobilizers for high dose chemotherapy and autologous stem cell transplantation?

Atilla P. A., Ozturk S. M. B., DEMİRER T.

TRANSFUSION AND APHERESIS SCIENCE , vol.56, no.2, pp.190-198, 2017 (SCI-Expanded, Scopus)

62. Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now?

Atilla E., Atilla P. A., DEMİRER T.

INTERNATIONAL JOURNAL OF HEMATOLOGY , vol.105, no.3, pp.257-264, 2017 (SCI-Expanded, Scopus)

63. An overview of high dose chemotherapy with autologous stem cell rescue for germ cell tumors in current practice

Ozaydin S., Sahin U., Karadurmus N., Arpaci F., DEMİRER T.

JOURNAL OF BUON , vol.22, no.2, pp.306-311, 2017 (SCI-Expanded, Scopus) Sustainable Development

64. Catheter Thrombosis in Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) Recipients

GÜRMAN G., Atilla E., Atilla P. A., CİVRİZ BOZDAĞ S., Yuksel M. K., TOPRAK S. K., et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION , vol.23, no.3, 2017 (SCI-Expanded)

65. Allogeneic Transplantation in Chronic Myeloid Leukemia and the Effect of Tyrosine Kinase Inhibitors on Survival: A Quasi-Experimental Study

Ozen M., Ustun C., Ozturk B., TOPÇUOĞLU P., Arat M., Gunduz M., et al.

TURKISH JOURNAL OF HEMATOLOGY , vol.34, no.1, pp.16-26, 2017 (SCI-Expanded, Scopus, TRDizin)

66. A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations

Atilla E., Atilla P. A., DEMİRER T.

BALKAN MEDICAL JOURNAL , vol.34, no.1, pp.1-9, 2017 (SCI-Expanded, Scopus, TRDizin)

67. Re: Iron overload in hematopoietic stem cell transplantation Re: Hematopoetik kök hücre transplantasyonunda aşırı demir yüklenmesi

Atilla E., TOPRAK S. K., DEMİRER T.

Turkish Journal of Hematology , vol.34, no.1, pp.103, 2017 (SCI-Expanded, Scopus, TRDizin)

68. Current Review of Iron Overload and Related Complications in Hematopoietic Stem Cell Transplantation

Atilla E., TOPRAK S. K., DEMİRER T.

TURKISH JOURNAL OF HEMATOLOGY , vol.34, no.1, pp.1-9, 2017 (SCI-Expanded, Scopus, TRDizin)

69. Iron Overload in Hematopoietic Stem Cell Transplantation Reply

Atilla E., TOPRAK S. K., Demirer T.

TURKISH JOURNAL OF HEMATOLOGY , vol.34, no.1, pp.103, 2017 (SCI-Expanded, Scopus, TRDizin)

70. Hairy Cell Leukemia Presenting with Isolated Bone Lesions

GÜNDÜZ M., ÖZEN M., YÜKSEL S., KUZU I., DEMİRER T.

LLM Dergi , vol.1, no.1, pp.14-17, 2017 (TRDizin)

71. Therapeutic Plasma Exchange for Thrombotic Microangiopathy

Ilhan O., Atilla E., Ataca Atilla P., Civriz Bozdag S., Kurt Yuksel M., Toprak S. K., et al.

BLOOD , vol.128, no.22, pp.4939, 2016 (SCI-Expanded, Scopus)

72. An overview of hematopoietic stem cell transplantation related thrombotic complications

Sahin U., Atilla P. A., Atilla E., TOPRAK S. K., DEMİRER T.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY , vol.107, pp.149-155, 2016 (SCI-Expanded, Scopus)

73. An overview of infectious complications after allogeneic hematopoietic stem cell transplantation

Sahin U., TOPRAK S. K., Atilla P. A., Atilla E., DEMİRER T.

JOURNAL OF INFECTION AND CHEMOTHERAPY , vol.22, no.7-8, pp.505-514, 2016 (SCI-Expanded, Scopus)

74. A Quasi-Experimental Study Analyzing the Effectiveness of Portable High-Efficiency Particulate Absorption Filters in Preventing Infections in Hematology Patients during Construction

Ozen M., Yilmaz G., Coskun B., TOPÇUOĞLU P., Ozturk B., Gunduz M., et al.

TURKISH JOURNAL OF HEMATOLOGY , vol.33, no.1, pp.41-47, 2016 (SCI-Expanded, Scopus, TRDizin)

75. Review of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in solid tumors excluding breast cancer

KARADURMUS N., ŞAHİN U., BASGOZ B. B., ARPACI F., DEMİRER T.

World Journal of Transplantation , vol.6, no.4, pp.675-681, 2016 (Peer-Reviewed Journal)

76. High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Breast Cancer: Is There Still a Hope?

DEMİRER T.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.26, no.3, pp.182-187, 2016 (SCI-Expanded, Scopus, TRDizin) Sustainable Development

77. Non-Infectious Early Complications of Allogeneic Stem Cell Transplantations

Atilla P. A., Atilla E., TOPRAK S. K., DEMİRER T.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.26, no.4, pp.239-250, 2016 (SCI-Expanded, Scopus, TRDizin) Sustainable Development

78. Is Initial CD3+ T Cell Dose in Donor Lymphocyte Infusion for Relapsed Hematological Malignancies a Prognostic Determinant?

Atilla E., Ataca P., Toprak S. K., Yuksel M. K., Topcuoglu P., Arslan O., et al.

BLOOD , vol.126, no.23, pp.5483, 2015 (SCI-Expanded, Scopus)

79. Comparison of Two Different Doses of Corticosteroid Premedication for Antithymocyte Globulin in Allogeneic Hematopoietic Stem Cell Transplantation

Merter M., Atilla E., Sahin U., Civriz Bozdag S., Kurt Yuksel M., Topcuoglu P., et al.

BLOOD , vol.126, no.23, pp.5456, 2015 (SCI-Expanded, Scopus)

80. Positive Impact of Chronic Graft-Versus Host Disease on Survival in 928 Allogeneic Hematopoietic Stem Cell Transplant Recipients

Gurman G., Ataca P., Atilla E., Civriz Bozdag S., Toprak S. K., Yuksel M. K., et al.

BLOOD , vol.126, no.23, pp.1952, 2015 (SCI-Expanded, Scopus)

81. Erythropoiesis-stimulating agents in allogeneic and autologous hematopoietic stem cell transplantation

Martino M., Lanza F., DEMİRER T., Moscato T., Secondino S., Pedrazzoli P.

EXPERT OPINION ON BIOLOGICAL THERAPY , vol.15, no.2, pp.195-211, 2015 (SCI-Expanded, Scopus) Sustainable Development

82. Antilymphocyte/Thymocyte Globulin for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease: 20-Year Experience at a Single Center

Ozen M., CİVRİZ BOZDAĞ S., Cakmak G., TOPÇUOĞLU P., Eroglu A. H., Glunduz M., et al.

UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI , vol.25, no.4, pp.236-244, 2015 (SCI-Expanded, Scopus, TRDizin)

83. Treatment Approaches in Acute Leukemia Patients Relapsing Following Allogeneic Hematopoietic Stem Cell Transplantation

Topcuoglu P., Gunduz M., Ozen M., Civriz Bozdag S., Kocak Toprak S., Arslan O., et al.

BLOOD , vol.124, no.21, pp.5891, 2014 (SCI-Expanded, Scopus)

84. Fertility in Our Allogeneic Hematopoietic Stem Cell Transplant Patients

Topcuoglu P., Ataca P., Bozdag S. C., Toprak S. K., Arslan O., Ozcan M., et al.

BLOOD , vol.124, no.21, pp.5887, 2014 (SCI-Expanded, Scopus)

85. Do FMS-like Tyrosine Kinase 3 and Nucleophospmin 1 Gene Mutations Really Effect Survival in Acute Myeloid Leukemia ?

Gunduz M., Ataca P., Ozen M., Atilla E., Bozdag S. C., Toprak S. K., et al.

BLOOD , vol.124, no.21, pp.5328, 2014 (SCI-Expanded, Scopus)

86. Is R-CODOX-M/IVAC Inferior to Other Regimens in Burkitt’s Lymphoma: A Single Center Experience

Atilla E., Sahin U., Ataca P., Uslu A., Kircali E., Atesagaoglu B., et al.

BLOOD , vol.124, no.21, pp.5448, 2014 (SCI-Expanded, Scopus)

87. Clinical Reflection of Immunophenotyping in Paroxysmal Nocturnal Hemoglobinuria: Experience of a Single Center

Sahin U., Merter M., Ataca P., Atilla E., Atesagaoglu B., Pekcan G., et al.

BLOOD , vol.124, no.21, pp.5150, 2014 (SCI-Expanded, Scopus)

88. Is the Chronic Myeloproliferative Disease Prognosis Really Different in Geriatric Patients?

Ilhan O., Ataca P., Atilla E., Toprak S. K., Kaygusuz G., Kuzu I., et al.

BLOOD , vol.124, no.21, pp.5555, 2014 (SCI-Expanded, Scopus)

89. Response to: 'Are there still reasons to believe that high-dose chemotherapy plays a role in breast cancer management?'

DEMİRER T.

Bone Marrow Transplantation , vol.48, no.2, pp.306, 2013 (SCI-Expanded, Scopus)

90. Intense Ga-68 Dotatate Uptake in Recurrent MTC Patient

SOYDAL Ç., ÖZKAN E., ARAZ M., KÜÇÜK N. Ö., DEMİRER T.

World Journal of Endocrine Surgery , vol.4, no.3, pp.118-119, 2012 (Scopus)

91. Novel agents and approaches for stem cell mobilization in normal donors and patients

Bakanay Ş., DEMİRER T.

Bone Marrow Transplantation , vol.47, no.9, pp.1154-1163, 2012 (SCI-Expanded, Scopus)

92. Intense ga-68 dotatate uptake in recurrent mtc patients

SOYDAL Ç., ÖZKAN E., ARAZ M., KÜÇÜK N. Ö., DEMİRER T.

WORLD JOURNAL OF ENDOCRINE SURGERY , vol.4, no.3, pp.118-119, 2012 (Scopus)

93. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: Overview of six randomized trials

Berry D. A., Ueno N. T., Johnson M. M., Lei X., Caputo J., Smith D. A., et al.

Journal of Clinical Oncology , vol.29, no.24, pp.3224-3231, 2011 (SCI-Expanded, Scopus)

94. High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: Overview of 15 randomized trials

Berry D. A., Ueno N. T., Johnson M. M., Lei X., Caputo J., Rodenhuis S., et al.

Journal of Clinical Oncology , vol.29, no.24, pp.3214-3223, 2011 (SCI-Expanded, Scopus)

95. Allogeneic hematopoietic stem cell transplantation in ovarian cancer - The EBMT experience

Bay J., Cabrespine-Faugeras A., Tabrizi R., Blaise D., Viens P., Ehninger G., et al.

International Journal of Cancer , vol.127, no.6, pp.1446-1452, 2010 (SCI-Expanded, Scopus) Sustainable Development

96. Mobilization of PBSCs with chemotherapy and recombinant human G-CSF: a randomized evaluation of early vs late administration of recombinant human G-CSF

Ozcelik T., Topcuoglu P., BEKSAÇ M., Ozcan M., Arat M., Biyikli Z., et al.

BONE MARROW TRANSPLANTATION , vol.44, no.12, pp.779-783, 2009 (SCI-Expanded, Scopus)

97. Severe Henoch-Schonlein Purpura Induced by Cytarabine

Aktas B., TOPÇUOĞLU P., Kurt O. K., ENSARİ A., Demirer T.

ANNALS OF PHARMACOTHERAPY , vol.43, no.4, pp.792-793, 2009 (SCI-Expanded, Scopus)

98. Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation in Metastatic Colorectal Cancer as a Novel Adoptive Cell Therapy Approach. The European Group for Blood and Marrow Transplantation Experience

Aglietta M., Barkholt L., Schianca F. C., Caravelli D., Omazic B., Minotto C., et al.

Biology of Blood and Marrow Transplantation , vol.15, no.3, pp.326-335, 2009 (SCI-Expanded, Scopus) Sustainable Development

99. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloblastic leukemia (AML): A single center experience

İLHAN O., TOPÇUOĞLU P., Arat M., Soydan E. A., YÜKSEL M., ARSLAN Ö., et al.

Turkish Journal of Hematology , vol.25, no.2, pp.87-93, 2008 (SCI-Expanded, Scopus, TRDizin)

100. 28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures

Ladenstein R., Poetschger U., Hartman O., Pearson A. D. J., Klingebiel T., Castel V., et al.

BONE MARROW TRANSPLANTATION , vol.41, 2008 (SCI-Expanded, Scopus)

101. Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors

DEMİRER T., Barkholt L., Blaise D., Pedrazzoli P., Aglietta M., Carella A. M., et al.

NATURE CLINICAL PRACTICE ONCOLOGY , vol.5, no.5, pp.256-267, 2008 (SCI-Expanded, Scopus) Sustainable Development

102. Allogeneic hematopoietic cell transplantation for metastatic breast cancer

Ueno N. T., Rizzo J. D., Demirer T., Cheng Y. C., Hegenbart U., Zhang M., et al.

BONE MARROW TRANSPLANTATION , vol.41, no.6, pp.537-545, 2008 (SCI-Expanded, Scopus)

103. High-dose chemotherapy with peripheral blood progenitor cell support for patients with non-small cell lung cancer: The experience of the European Group for Bone Marrow Transplantation (EBMT) Solid Tumours Working Party

De Giorgi U., Blaise D., Lange A., Viens P., Marangolo M., Madroszyk A., et al.

BONE MARROW TRANSPLANTATION , vol.40, no.11, pp.1045-1048, 2007 (SCI-Expanded, Scopus)

104. High-dose chemotherapy with autologous hematopoietic stem cell support for solid tumors in adults

Pedrazzoli P., Rosti G., Secondino S., Carminati O., Demirer T.

SEMINARS IN HEMATOLOGY , vol.44, no.4, pp.286-295, 2007 (SCI-Expanded, Scopus)

105. Reduced intensity stem cell transplantation for advanced soft tissue sarcomas in adults: a retrospective analysis of the European Group for Blood and Marrow Transplantation

Secondino S., Carrabba M. G., Pedrazzoli P., Castagna L., Spina F., Grosso F., et al.

HAEMATOLOGICA , vol.92, no.3, pp.418-420, 2007 (SCI-Expanded, Scopus)

106. High dose chemotherapy with autologous hematopoietic stem cell support for solid tumors other than breast cancer in adults

Pedrazzoli P., Ledermann J. A., Lotz J. -., Leyvraz S., Aglietta M., Rosti G., et al.

ANNALS OF ONCOLOGY , vol.17, no.10, pp.1479-1488, 2006 (SCI-Expanded, Scopus) Sustainable Development

107. Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe

Barkholt L., Bregni M., Remberger M., Blaise D., Peccatori J., Massenkeil G., et al.

ANNALS OF ONCOLOGY , vol.17, no.7, pp.1134-1140, 2006 (SCI-Expanded, Scopus) Sustainable Development

108. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe

Ljungman P., Urbano-Ispizua A., Cavazzana-Calvo M., Demirer T., Dini G., Einsele H., et al.

BONE MARROW TRANSPLANTATION , vol.37, no.5, pp.439-449, 2006 (SCI-Expanded, Scopus)

109. Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation

Peccatori J., Barkholt L., Demirer T., Sormani M., Bruzzi P., Ciceri F., et al.

CANCER , vol.104, no.10, pp.2099-2103, 2005 (SCI-Expanded, Scopus)

110. Salvage high-dose chemotherapy for children with extragonadal germ-cell tumours

De Giorgi U., Rosti G., Slavin S., Yaniv I., Harousseau J., Ladenstein R., et al.

BRITISH JOURNAL OF CANCER , vol.93, no.4, pp.412-417, 2005 (SCI-Expanded, Scopus)

111. High-dose chemotherapy with autologous haemopoietic support for advanced ovarian cancer in first complete remission: retrospective analysis from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT)

Bengala C., Guarneri V., Ledermann J., Rosti G., Wandt H., Lotz J., et al.

BONE MARROW TRANSPLANTATION , vol.36, no.1, pp.25-31, 2005 (SCI-Expanded, Scopus)

112. Second-line high-dose chemotherapy in patients with mediastinal and retroperitoneal primary non-seminomatous germ cell tumors: the EBMT experience

De Giorgi U., Demirer T., Wandt H., Taverna C., Siegert W., Bornhauser M., et al.

ANNALS OF ONCOLOGY , vol.16, no.1, pp.146-151, 2005 (SCI-Expanded, Scopus)

113. First-line high-dose chemotherapy for patients with poor prognosis extragonadal germ cell tumors: the experience of the European Bone Marrow Transplantation (EBMT) Solid Tumors Working Party

Rosti G., De Giorgi U., Wandt H., Lioure B., Leyvraz S., Kolbe K., et al.

BONE MARROW TRANSPLANTATION , vol.34, no.12, pp.1033-1037, 2004 (SCI-Expanded, Scopus)

114. Allogeneic Hemapoietic Progenitor Cell Collection Using Four Different Cell Separators: A Retrospective Comparative Analysis.

Arat M., Arslan O., Soydan E. A., Ayyildiz E., Dalva K., Tol M., et al.

BLOOD , vol.104, no.11, pp.5009, 2004 (SCI-Expanded, Scopus)

115. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation in patients with lymphoma - A retrospective evaluation

Demirer T., Ayli M., Fen T., Ozcan M., Arat M., Buyukberber S., et al.

Bone Marrow Transplantation , vol.34, no.9, pp.781-786, 2004 (SCI-Expanded, Scopus)

116. The Comparison of Myeloablative Versus Reduced Intensity Conditioning Regimen in ABO Mismatched Allogeneic Hematopoietic Cell Transplantation.

Topcuoglu P., Arat M., Bolukbasi T., Soydan E., Ozer Y., Ozcan M., et al.

BLOOD , vol.104, no.11, pp.5146, 2004 (SCI-Expanded, Scopus)

117. Hematopoetic stem cell transplantation for solid tumors in Europe

Gratwohl A., Baldomero H., Demirer T., Rosti G., Dini G., Ladenstein R., et al.

ANNALS OF ONCOLOGY , vol.15, no.4, pp.653-660, 2004 (SCI-Expanded, Scopus)

118. Second-line high-dose chemotherapy in patients with extragonadial nonseminomatous germ cell tumors: the experience of the European Group for Blood and Marrow Transplantation (EBMT)

De Giorgi U., DEMİRER T., Wandt H., Taverna C., Siegert W., Borhauser M., et al.

ANNALS OF ONCOLOGY , vol.15, pp.121, 2004 (SCI-Expanded, Scopus)

119. Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients

Kroger N., Damon L., Zander A., Wandt H., Derigs G., Ferrante P., et al.

BONE MARROW TRANSPLANTATION , vol.32, no.12, pp.1153-1157, 2003 (SCI-Expanded, Scopus)

120. Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990-1999

Pedrazzoli P., Ferrante P., Kulekci A., Schiavo R., De Giorgi U., Carminati O., et al.

BONE MARROW TRANSPLANTATION , vol.32, no.5, pp.489-494, 2003 (SCI-Expanded, Scopus)

121. High-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous stem cell transplantation in patients with advanced breast cancer: a retrospective evaluation

Demirer T., Uysal V., Ayli M., Genc Y., Ilhan O., Koc H., et al.

BONE MARROW TRANSPLANTATION , vol.31, no.9, pp.755-761, 2003 (SCI-Expanded, Scopus)

122. Low incidence of secondary myelodysplasia and acute myeloid leukemia after high-dose chemotherapy as adjuvant therapy for breast cancer patients: a study by the Solid Tumors Working Party of the European Group for Blood and Marrow Transplantation

Kroger N., Zander A., Martinelli G., Ferrante P., Moraleda J., Da Prada G., et al.

ANNALS OF ONCOLOGY , vol.14, no.4, pp.554-558, 2003 (SCI-Expanded, Scopus) Sustainable Development

123. CD34+ cells in hematopoietic stem cell transplantation

DEMİRER T.

Advances in Experimental Medicine and Biology , vol.534, pp.107-118, 2003 (Scopus)

124. CD34+cells in hematopoietic stem cell transplantation

Demirer T.

TISSUE ENGINEERING, STEM CELLS AND GENE THERAPIES , vol.534, pp.107-118, 2003 (SCI-Expanded, Scopus)

125. The role of ABO incompatibility in allogeneic peripheral blood stem cell transplantation

ARSLAN Ö., Coşkun H. Ş., Arat M., Soydan E., ÖZCAN M., GÜRMAN G., et al.

Turkish Journal of Haematology , vol.19, no.3, pp.401-409, 2002 (SCI-Expanded, Scopus, TRDizin)

126. The effect of post-transplant spironolactone on daily potassium requirements in patients undergoing autologous stem cell transplantation

Demirer T., Ayli M., Dagli M., Fen T., Haznedar R., Ustael N., et al.

BONE MARROW TRANSPLANTATION , vol.30, no.10, pp.703-704, 2002 (SCI-Expanded, Scopus)

127. Monitoring of peripheral blood CD34+cell counts on the first day of apheresis is highly predictive for efficient CD34+cell yield

Demirer T., Ilhan O., Ayli M., Arat M., Dagli M., Ozcan M., et al.

THERAPEUTIC APHERESIS , vol.6, no.5, pp.384-389, 2002 (SCI-Expanded)

128. The Role of ABO Incompatibility in Allogeneic Peripheral Blood Stem Cell Transplant.

Arslan Ö., Coşkun H. Ş., Arat M., Soydan E., Özcan M., Gürman G., et al.

Turkish journal of haematology : official journal of Turkish Society of Haematology , vol.19, no.3, pp.401-9, 2002 (Scopus, TRDizin)

129. Influence of post-transplant recombinant human granulocyte colony-stimulating factor administration on peritransplant morbidity in patients undergoing autologous stem cell transplantation.

Demirer T., Ayli M., Dagli M., Haznedar R., Genc Y., Fen T., et al.

British journal of haematology , vol.118, no.4, pp.1104-11, 2002 (SCI-Expanded, Scopus)

130. A randomized trial of assessment of efficacy of leukapheresis volumes, 8 liters vs 12 liters

Demirer T., Dagli M., Ilhan O., Ayli M., Haznedar R., Fen T., et al.

BONE MARROW TRANSPLANTATION , vol.29, no.11, pp.893-897, 2002 (SCI-Expanded, Scopus)

131. Does donor recipient ABO-incompatibility have any effect on the course and outcome of allogeneic hematopoietic cell transplantation?

Arslan O., Arat M., Soydan E., COŞKUN H. Ş., Topcuoglu P., Ozcan M., et al.

BONE MARROW TRANSPLANTATION , vol.29, 2002 (SCI-Expanded, Scopus)

132. Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF

Demirer T., Ayli M., Ozcan M., Gunel N., Haznedar R., Dagli M., et al.

BRITISH JOURNAL OF HAEMATOLOGY , vol.116, no.2, pp.468-474, 2002 (SCI-Expanded, Scopus)

133. Plasmacytoma in the bilateral breast

Daǧli M., DEMİRER T., Ayli M., Haznedar R., GÜNEL N., Sucak G., et al.

Turkish Journal of Haematology , vol.19, no.4, pp.481-483, 2002 (SCI-Expanded, Scopus, TRDizin)

134. An unusual presentation of plasma cell dyscrasias: cardiac tamponade due to myelomatous infiltration.

Arat M., Ulusoy V., Demirer T., Uysal A., Ozcan M., Dincer S., et al.

Leukemia & lymphoma , vol.43, no.1, pp.145-8, 2002 (SCI-Expanded)

135. Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte-colony stimulating factor (rh-GSCF): A randomized evaluation of different doses of rh-G-CSF.

Demirer T., Ayli M., Arat M., Ozcan M., Gunel N., Haznedar R., et al.

BLOOD , vol.98, no.11, 2001 (SCI-Expanded, Scopus)

136. A randomized trial of assessment of efficacy of leukapheresis volumes, 8 L versus 10L.

Demirer T., Ayli M., Arat M., Gunel N., Ozcan M., Haznedar R., et al.

BLOOD , vol.98, no.11, 2001 (SCI-Expanded, Scopus)

137. CD41+ and CD42+ hematopoietic progenitor cells may predict platelet engraftment after allogeneic peripheral blood stem cell transplantation

DEMİRER T., Ilhan O., Arat M., YAVUZ Y., ÖZCAN M. E., DALVA K., et al.

Journal of Clinical Apheresis , vol.16, no.2, pp.67-73, 2001 (SCI-Expanded, Scopus)

138. High-dose Thiotepa, Melphalan and Carboplatin (TMCB) with autologous Peripheral Blood Stem Cell (PBSC) support in patients with hematologic malignancies and solid tumors

Demirer T., Ilhan O., Ayli M., Arat M., Fen T., Ozcan M., et al.

BONE MARROW TRANSPLANTATION , vol.27, 2001 (SCI-Expanded, Scopus)

139. Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation

Ozcan M., Ustun C., Akcaglayan E., Akan H., Arslan O., Ilhan O., et al.

BONE MARROW TRANSPLANTATION , vol.27, no.5, pp.499-505, 2001 (SCI-Expanded, Scopus)

140. CD41+and CD42+hematopoietic progenitor cells may predict platelet engraftment after allogeneic peripheral blood stem cell transplantation

Demirer T., Ilhan O., Arat M., Genc Y., Ozcan M., Dalva K., et al.

JOURNAL OF CLINICAL APHERESIS , vol.16, no.2, pp.67-73, 2001 (SCI-Expanded, Scopus)

141. Phase-II study of high-dose thiotepa, melphalan and carboplatin (TMCb) with autologous peripheral blood stem cell (PBSC) support in patients with hematologic malignancies and solid tumors.

Demirer T., Ilhan O., Ayli M., Arat M., Fen T., Haznedar R., et al.

BLOOD , vol.96, no.11, 2000 (SCI-Expanded, Scopus)

142. Peripheral blood stem cell (PBSC) collection with cyclophosphamide (CY), etoposide and recombinant human granulocyte-colony stimulating factor (rhG-CSF) in patients with hematologic malignancies and solid tumors.

Demirer T., Ayli M., Demirer A., Fen T., Haznedar R., Celik Z., et al.

BLOOD , vol.96, no.11, 2000 (SCI-Expanded, Scopus)

143. Peripheral blood stem cell (PBSC) collection with cyclophosphamide (CY), epirubicin and recombinant human granulocyte-colony stimulating factor (rhG-CSF) in patients with breast and ovarian cancer.

Demirer T., Ayli M., Demirer A., Ulusoy V., Fen T., Celik Z., et al.

BLOOD , vol.96, no.11, 2000 (SCI-Expanded, Scopus) Sustainable Development

144. The value of peripheral blood CD34(+) cell quantification in autologous hematopoietic stem cell apheresis.

Ilhan O., Arslan O., Arat M., Ozcan M., GÜRMAN G., Dalva K., et al.

BLOOD , vol.96, no.11, 2000 (SCI-Expanded, Scopus)

145. Comparison of the efficacy of medium chain triglycerides with long chain triglycerides in total parenteral nutrition in patients with hematologic malignancies undergoing peripheral blood stem cell transplantation

Demirer S., Aydintug S., Ustun C., Turkmen E., Tuzun A., Simsek S., et al.

CLINICAL NUTRITION , vol.19, no.4, pp.253-258, 2000 (SCI-Expanded, Scopus)

146. Allogeneic peripheral blood stem cell transplantation for standard risk leukemia: experience of Ibni Sina Hospital

Arslan O., COŞKUN H. Ş., Arat M., Celebi H., Ozcan M., GÜRMAN G., et al.

BONE MARROW TRANSPLANTATION , vol.25, no.12, pp.1229-1232, 2000 (SCI-Expanded, Scopus)

147. A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignancies

Demirer T., Ilhan O., Mandel N., Arat M., Gunel N., Celebi H., et al.

BONE MARROW TRANSPLANTATION , vol.25, no.7, pp.697-703, 2000 (SCI-Expanded, Scopus)

148. Primary low-grade lymphomas of the intestine - Case 1: Immunoproliferative small intestinal disease

Demirer T., Celebi H., Akcaglayan E., Ustun C., Demirer S., Ekinci C., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.17, no.11, pp.3682-3684, 1999 (SCI-Expanded, Scopus)

149. Treatment of aregeneratoric anemia following an ABO-incompatible allogeneic peripheral blood stem cell transplantation: A case report

Üstün C., Çelebi H., Arat M., ÖZCAN M., Dilek I., GÜRMAN G., et al.

Therapeutic Apheresis , vol.3, no.3, pp.275-277, 1999 (SCI-Expanded)

150. Autoimmune thrombocytopenia in a patient with small cell lung cancer developing after chemotherapy and resolving following autologous peripheral blood stem cell transplantation

Demirer T., Celebi H., Arat M., Ustun C., Demirer S., Dilek I., et al.

BONE MARROW TRANSPLANTATION , vol.24, no.3, pp.335-337, 1999 (SCI-Expanded, Scopus)

151. Peripheral blood stem cell mobilization for high-dose chemotherapy

Demirer T., Bensinger W., Buckner C.

JOURNAL OF HEMATOTHERAPY , vol.8, no.2, pp.103-113, 1999 (SCI-Expanded, Scopus)

152. The effect of G-CSF in the first 100 days of allogeneic peripheral blood stem cell transplantation.

Ozcan M., Ustun C., Ilhan O., Beksac M., Akcaglayan E., GÜRMAN G., et al.

BONE MARROW TRANSPLANTATION , vol.23, 1999 (SCI-Expanded, Scopus)

153. The influence of CD41+ and CD42+ peripheral blood stem cells on platelet engraftment after allo PBSCT.

Ilhan O., Demirer T., Arat M., Dalva K., COŞKUN H. Ş., BEKSAÇ M., et al.

BONE MARROW TRANSPLANTATION , vol.23, 1999 (SCI-Expanded, Scopus)

154. Clinical effects of intravenous immune globulin (IVIG) treatment in patients with allogeneic peripheral stem cell transplantation.

Ustun C., Ozcan M., Beksac M., Ilhan O., Cakir M., GÜRMAN G., et al.

BONE MARROW TRANSPLANTATION , vol.23, 1999 (SCI-Expanded, Scopus)

155. Peripheral blood stem cell (PBSC) collection with cyclophosphamide (CY) - Paclitaxel and recombinant human granulocyte-colony stimulating factor (rhG-CSF) in patients with breast cancer: Ibni Sina experience

Arat M., Demirer T., Ilhan O., Koc H., Ustun C., Celebi H., et al.

BONE MARROW TRANSPLANTATION , vol.23, 1999 (SCI-Expanded, Scopus) Sustainable Development

156. Allogeneic hematopoietic cell transplantation in patients with advanced hematological malignancies by using nonmyeloablative conditioning regimen.

GÜRMAN G., Ustun C., Arslan O., BEKSAÇ M., Konuk N., Arat M., et al.

BONE MARROW TRANSPLANTATION , vol.23, 1999 (SCI-Expanded, Scopus)

157. A protocol proposal comparing conventional approach with high-dose chemotherapy (HDC) and peripheral blood stem cell transplantation (PBSCT) in patients with small cell lung cancer limited to thorax.

Demirer T., Arat M., Koc H., Ilhan O., Celebi H., Ozcan M., et al.

BONE MARROW TRANSPLANTATION , vol.23, 1999 (SCI-Expanded, Scopus) Sustainable Development

158. Differences in liver pathology and clinical outcome between two patients with Hepatitis B virus and graft versus host disease

Üstün C., ÖZCAN M., GÜRMAN G., Çakir M., Erekul S., AKYOL G., et al.

Pathology and Oncology Research , vol.5, no.3, pp.229-232, 1999 (SCI-Expanded, Scopus) Sustainable Development

159. A retrospective comparison of allogeneic peripheral blood stem cell and bone marrow transplantation results from a single center: A focus on the incidence of graft-vs.-host disease and relapse

Üstün C., ARSLAN Ö., BEKSAÇ M., Koç H., GÜRMAN G., Özçelik T., et al.

Biology of Blood and Marrow Transplantation , vol.5, no.1, pp.28-35, 1999 (SCI-Expanded, Scopus) Sustainable Development

160. Clinical effects of intravenous immune globulin (IVIG) treatment in patients with allogeneic peripheral stem cell transplantation.

Ustun C., Ozcan M., BEKSAÇ M., Ilhan O., Cakir M., GÜRMAN G., et al.

BLOOD , vol.92, no.10, 1998 (SCI-Expanded, Scopus)

161. The effect of G-CSF in the first 100 days of allogeneic peripheral blood stem cell transplantation.

Ozcan M., Ustun C., Ilhan O., BEKSAÇ M., Akcaglayan E., GÜRMAN G., et al.

BLOOD , vol.92, no.10, 1998 (SCI-Expanded, Scopus)

162. Allogeneic hematopoietic stem cell transplantation in patients with advanced hematological malignancies by using nonmyeloablative conditioning regimen.

GÜRMAN G., Ustun C., Arslan O., BEKSAÇ M., Konuk N., Arat M., et al.

BLOOD , vol.92, no.10, 1998 (SCI-Expanded, Scopus)

163. Which hematopoietic stem cell transplantation type is safe for patients with hepatitis B virus carriers.

Ustun C., Idilman R., Ozcan M., Akan H., Karayalcin S., GÜRMAN G., et al.

HEPATOLOGY , vol.28, no.4, 1998 (SCI-Expanded, Scopus) Sustainable Development

164. Acute myeloblastic leukemia associated with hyperleukocytosis and diabetes insipidus

Dilek I., Uysal A., Demirer T., Koc H., Ozcan M., Keles H., et al.

LEUKEMIA & LYMPHOMA , vol.30, no.5-6, pp.657-660, 1998 (SCI-Expanded, Scopus) Sustainable Development

165. Acquired ichthyosis associated with chronic graft-versus-host disease following allogeneic peripheral blood stem cell transplantation in a patient with chronic myelogenous leukemia

Dilek I., Demirer T., Ustun C., Arat M., Koc H., BEKSAÇ M., et al.

BONE MARROW TRANSPLANTATION , vol.21, no.11, pp.1159-1161, 1998 (SCI-Expanded, Scopus)

166. Tempo of hematologic recovery correlates with peripheral blood CD34+ cell level in patients undergoing stem cell mobilization

Williams O., DEMİRER T., Lilleby K., Buckner C. D., Bensinger W.

Journal of Clinical Apheresis , vol.13, no.1, pp.1-6, 1998 (SCI-Expanded, Scopus)

167. High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cell (PBSC) rescue in patients with advanced stage III/IV ovarian cancer

Holmberg L., Demirer T., Rowley S., Buckner C., Goodman G., Maziarz R., et al.

BONE MARROW TRANSPLANTATION , vol.22, no.7, pp.651-659, 1998 (SCI-Expanded, Scopus) Sustainable Development

168. Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor

Demirer T., Buckner C., Storer B., Lilleby K., Rowley S., Clift R., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.15, no.2, pp.684-690, 1997 (SCI-Expanded, Scopus) Sustainable Development

169. Transplantation of allogeneic CD34+ peripheral blood stem cells in patients with advanced hematologic malignancy

Bensinger W., Buckner C., Shannon-Dorcy K., Rowley S., Appelbaum F., Benyunes M., et al.

Blood , vol.88, no.11, pp.4132-4138, 1996 (Scopus)

170. Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: A retrospective comparison with marrow transplantation

Bensinger W., Clift R., Martin P., Appelbaum F., Demirer T., Gooley T., et al.

BLOOD , vol.88, no.7, pp.2794-2800, 1996 (SCI-Expanded, Scopus)

171. Syngeneic marrow transplantation in patients with multiple myeloma

Bensinger W., DEMİRER T., Buckner C., Appelbaum F., Storb R., Lilleby K., et al.

Bone Marrow Transplantation , vol.18, no.3, pp.527-531, 1996 (SCI-Expanded, Scopus)

172. Autologous transplantation with peripheral blood stem cells collected after granulocyte colony-stimulating factor in patients with acute myelogenous leukemia

DEMİRER T., Petersen F., Bensinger W., Appelbaum F., Fefer A., Rowley S., et al.

Bone Marrow Transplantation , vol.18, no.1, pp.29-34, 1996 (SCI-Expanded, Scopus)

173. High-dose fractionated total-body irradiation, etoposide and cyclophosphamide for treatment of malignant lymphoma: Comparison of autologous bone marrow and peripheral blood stem cells

Brunvand M., Bensinger W., Soll E., Weaver C., Rowley S., Appelbaum F., et al.

Bone Marrow Transplantation , vol.18, no.1, pp.131-141, 1996 (SCI-Expanded, Scopus)

174. Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease

Schiffman K., Bensinger W., Appelbaum F., Rowley S., Lilleby K., Clift R., et al.

Bone Marrow Transplantation , vol.17, no.6, pp.943-950, 1996 (SCI-Expanded, Scopus)

175. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma

DEMİRER T., Buckner C., Gooley T., Appelbaum F., Rowley S., Chauncey T., et al.

Bone Marrow Transplantation , vol.17, no.6, pp.937-941, 1996 (SCI-Expanded, Scopus)

176. High-dose busulfan and cyclophosphamide followed by autologous transplantation in patients with advanced breast cancer

DEMİRER T., Buckner C., Appelbaum F., Clift R., Storb R., Myerson D., et al.

Bone Marrow Transplantation , vol.17, no.5, pp.769-774, 1996 (SCI-Expanded, Scopus)

177. Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: Phase I dose escalation of busulfan based on targeted plasma levels

DEMİRER T., Buckner C., Appelbaum F., Bensinger W., Sanders J., Lambert K., et al.

Bone Marrow Transplantation , vol.17, no.4, pp.491-495, 1996 (SCI-Expanded, Scopus)

178. Transplantation of allogeneic CD34+ peripheral blood stem cells (PBSC) in patients with advanced hematologic malignancy

Bensinger W., Buckner C., Rowley S., DEMİRER T., Storb R., Appelbaum F., et al.

Bone Marrow Transplantation , vol.17, no.SUPPL. 2, 1996 (Scopus)

179. Busulfan, cyclophosphamide and fractionated total body irradiation for allogeneic marrow transplantation in advanced acute and chronic myelogenous leukemia: Phase I dose escalation of busulfan based on targeted plasma levels

DEMİRER T., Buckner C., Appelbaum F., Lambert K., Bensinger W., Clift R., et al.

Bone Marrow Transplantation , vol.17, no.3, pp.341-346, 1996 (SCI-Expanded, Scopus)

180. Optimization of peripheral flood stem cell mobilization

Demirer T., Buckner C., Bensinger W.

STEM CELLS , vol.14, no.1, pp.106-116, 1996 (SCI-Expanded, Scopus)

181. High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma

Bensinger W., Rowley S., Demirer T., Lilleby K., Schiffman K., Clift R., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.14, no.5, pp.1447-1456, 1996 (SCI-Expanded, Scopus) Sustainable Development

182. Transplantation of allogeneic peripheral blood stem cells.

Bensinger W., Buckner C., DEMİRER T., Storb R., Appelbaum F.

Bone marrow transplantation , vol.17 Suppl 2, 1996 (Scopus)

183. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony stimulating factor

Bensinger W., Clift R., Anasetti C., Appelbaum F., Demirer T., Rowley S., et al.

STEM CELLS , vol.14, no.1, pp.90-105, 1996 (SCI-Expanded, Scopus)

184. Rapid engraftment after autologous transplantation utilizing marrow and recombinant granulocyte colony-stimulating factor-mobilized peripheral blood stem cells in patients with acute myelogenous leukemia

DEMİRER T., Buckner C., Appelbaum F., Petersen F., Rowley S., Weaver C., et al.

Bone Marrow Transplantation , vol.15, no.6, pp.915-922, 1995 (Scopus)

185. ALLOGENEIC MARROW TRANSPLANTATION FOLLOWING CYCLOPHOSPHAMIDE AND ESCALATING DOSES OF HYPERFRACTIONATED TOTAL-BODY IRRADIATION IN PATIENTS WITH ADVANCED LYMPHOID MALIGNANCIES - A PHASE I/II TRIAL

DEMIRER T., PETERSEN F., APPELBAUM F., BARNETT T., SANDERS J., DEEG H., et al.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS , vol.32, no.4, pp.1103-1109, 1995 (SCI-Expanded, Scopus) Sustainable Development

186. FACTORS THAT INFLUENCE COLLECTION AND ENGRAFTMENT OF AUTOLOGOUS PERIPHERAL-BLOOD STEM-CELLS

BENSINGER W., APPELBAUM F., ROWLEY S., STORB R., SANDERS J., LILLEBY K., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.13, no.10, pp.2547-2555, 1995 (SCI-Expanded, Scopus) Sustainable Development

187. Optimization of peripheral blood stem cell collection.

DEMİRER T., Bensinger W.

Current opinion in hematology , vol.2, no.3, pp.219-226, 1995 (Scopus)

188. PERIPHERAL-BLOOD STEM-CELL COLLECTIONS AFTER PACLITAXEL, CYCLOPHOSPHAMIDE, AND RECOMBINANT HUMAN GRANULOCYTE-COLONY-STIMULATING FACTOR IN PATIENTS WITH BREAST AND OVARIAN-CANCER

DEMIRER T., ROWLEY S., BUCKNER C., APPELBAUM F., LILLEBY K., STORB R., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.13, no.7, pp.1714-1719, 1995 (SCI-Expanded, Scopus) Sustainable Development

189. HIGH-DOSE CYCLOPHOSPHAMIDE, CARMUSTINE, AND ETOPOSIDE FOLLOWED BY ALLOGENEIC BONE-MARROW TRANSPLANTATION IN PATIENTS WITH LYMPHOID MALIGNANCIES WHO HAD RECEIVED PRIOR DOSE-LIMITING RADIATION-THERAPY

DEMIRER T., WEAVER C., BUCKNER C., PETERSEN F., BENSINGER W., SANDERS J., et al.

JOURNAL OF CLINICAL ONCOLOGY , vol.13, no.3, pp.596-602, 1995 (SCI-Expanded, Scopus) Sustainable Development

190. FLOW CYTOMETRIC MEASUREMENT OF PROLIFERATION-ASSOCIATED NUCLEAR ANTIGEN P105 AND DNA CONTENT IN IMMUNO-PROLIFERATIVE SMALL-INTESTINAL DISEASE (IPSID)

DEMIRER T., UZUNALIMOGLU O., ANDERSON T., KOETHE S., MCFADDEN P., DEMIRER S., et al.

JOURNAL OF SURGICAL ONCOLOGY , vol.58, no.1, pp.25-30, 1995 (SCI-Expanded)

191. Influence of total nucleated cell dose from marrow harvests on outcome in patients with acute myelogenous leukemia undergoing autologous transplantation

DEMİRER T., Gooley T., Buckner C., Petersen F., Lilleby K., Rowley S., et al.

Bone Marrow Transplantation , vol.15, no.6, pp.907-913, 1995 (SCI-Expanded, Scopus)

192. Fatal bone marrow necrosis following fludarabine administration in a patient with indolent lymphoma

Aboulafia D. M., DEMİRER T.

Leukemia and Lymphoma , vol.19, no.1-2, pp.181-184, 1995 (SCI-Expanded, Scopus)

193. Failure of a single cycle of high dose cyclophosphamide followed by intensive myeloablative therapy and autologous stem cell transplantation to improve outcome in relapsed disease

DEMİRER T., Buckner C. D., Lilleby K., Weaver C., Longin K., Appelbaum F. R., et al.

Cancer , vol.74, no.2, pp.715-721, 1994 (Scopus)

194. Myasthenic (Eaton-Lambert) syndrome associated with pulmonary large-cell neuroendocrine carcinoma

DEMİRER T., Ravits J., Aboulafia D.

Southern Medical Journal , vol.87, no.11, pp.1186-1189, 1994 (SCI-Expanded, Scopus)

195. Four varied cases of intravascular lymphomatosis and a literature review

DEMİRER T., Dail D. H., Aboulafia D. M.

Cancer , vol.73, no.6, pp.1738-1745, 1994 (Scopus)

196. INTRATUMOR HETEROGENEITY OF DNA-PLOIDY AND CORRELATIONS WITH CLINICAL STAGE AND HISTOLOGIC GRADE IN PROSTATE-CANCER

KUCUK O., DEMIRER T., GILMANSACHS A., TAW I., MANGOLD M., SINGH S., et al.

JOURNAL OF SURGICAL ONCOLOGY , vol.54, no.3, pp.171-174, 1993 (SCI-Expanded, Scopus) Sustainable Development

197. DIET AND STOMACH-CANCER INCIDENCE - A CASE CONTROL STUDY IN TURKEY

DEMIRER T., ICLI F., UZUNALIMOGLU O., KUCUK O.

CANCER , vol.65, no.10, pp.2344-2348, 1990 (SCI-Expanded, Scopus) Sustainable Development

Papers Presented at Peer-Reviewed Scientific Conferences 216

1. YOĞUN İNDÜKSİYONA UYGUN AKUT MİYELOİD LÖSEMİ HASTALARINDA HİPOMETİLE EDİCİ İLAÇ-VENETOKLAKS İLE İNDÜKSİYON TEDAVİSİNİN SONUÇLARI

ÇALIŞ U., ŞAHİN U., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.

51.Ulusal Hematoloji kongresi, Turkey, 28 October 2025, (Full Text)

2. ATG KULLANILAN ALLOJENİK KÖK HÜCRE NAKLİNDE DAHA YÜKSEK TRASPLANTASYON ÖNCESİ LENFOSİT SAYISI SAĞKALIM ORANININ İYİLEŞMESİYLE İLİŞKİLİDİR

KÖKCÜ G., DALVA K., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., et al.

51.Ulusal Hematoloji kongresi, Turkey, 28 October - 02 November 2025, (Full Text)

3. NÜKS/DİRENÇLİ AKUT MYELOİD LÖSEMİ TEDAVİSİNDE FLAG-İDA İLE KOMBİNE VENETOKLAKS KULLANIMI: TEK MERKEZ DENEYİMİ

KÖKCÜ G., DALVA K., HANEDAR E., İŞİKAN H. E., SÖNMEZ G. M., BEKTAŞ M., et al.

51.Ulusal Hematoloji kongresi, Turkey, 28 October 2025, (Full Text)

4. İNFÜZE EDİLEN CD34+ VE CD3+ HÜCRE MİKTARININ VE CD34+/CD3+ ORANININ AKHN SONUÇLARINA ETKİLERİ

ŞEN T., KILIÇ Ö., ŞAHİN U., CENGİZ SEVAL G., YÜKSEL M., TOPÇUOĞLU P., et al.

51.Ulusal Hematoloji kongresi, Turkey, 28 October - 02 November 2025, (Full Text)

5. NÜKS/DİRENÇLİ AKUT MYELOİD LÖSEMİ TEDAVİSİNDE FLAG-İDA İLE KOMBİNE VENETOKLAKS KULLANIMI: TEK MERKEZ DENEYİMİ

KÖKCÜ G., DALVA K., HANEDAR E., SÖNMEZ G. M., BEKTAŞ M., YÜKSEL M., et al.

51.Ulusal Hematoloji kongresi, Turkey, 28 October - 02 November 2025, (Full Text)

6. SAÇLI HÜCRELİ LÖSEMİDE KLADRİBİN MONOTERAPİSİNİN UZUN DÖNEM SONUÇLARI VE NÜKSÜ ÖNGÖREN İMMÜNOFENOTİPİK BELİRTEÇLER

BEKTAŞ M., YURDAKUL B. E., DALVA K., ŞAHİN U., CENGİZ SEVAL G., TOPRAK S. K., et al.

51.Ulusal Hematoloji kongresi, Turkey, 28 October - 02 November 2025, (Full Text)

7. WHO VE ICC IŞIĞINDA MPN’LERİN GENETİK ÖZELLİKLERİ VE KLİNİK KORELASYONU

SÖNMEZ G. M., LEBLEBİCİ C. B., YÜRÜR KUTLAY N., CENGİZ SEVAL G., TOPRAK S. K., TOPÇUOĞLU P., et al.

51.Ulusal Hematoloji kongresi, Turkey, 28 October - 02 November 2025, (Full Text)

8. SPİNAL MANYETİK REZONANS GÖRÜLTÜLEMEDE ANORMAL KEMİK İLİĞİ YOĞUNLUĞUNUN HEMATOLOJİK HASTALIKLARLA İLİŞKİSİ

AYDOĞAN M., CENGİZ SEVAL G., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.

51.Ulusal Hematoloji kongresi, Turkey, 28 October - 02 November 2025, (Full Text)

9. PERİFERİK T HÜCRELİ LENFOMA TANILI HASTALARIN ANALİZİ: TEK MERKEZ DENEYİMİ

Yüksel M., Cengiz Seval G., Topçuoğlu P., Arslan Ö., Özcan M., Demirer T.

50.Ulusal Hematoloji Kongresi, Antalya, Turkey, 29 October - 02 November 2024, pp.136-137, (Full Text)

10. MİKOSİZ FUNGOİDES VE SEZARY SENDROMLU HASTALARDA BRENTUXİMAB VEDOTİN TEDAVİSİNİN UZUN DÖNEM SONUÇLARI

Yüksel M., Şanlı H., Dalva K., Cengiz Seval G., Topçuoğlu P., Arslan Ö., et al.

50.Ulusal Hematoloji Kongresi, Antalya, Turkey, 29 October - 02 November 2024, pp.111, (Full Text)

11. NÜKS DİRENÇLİ T HÜCRELİ LENFOMALARDA PRALATREKSAT KULLANIMI: TEK MERKEZ DENEYİMİ

SÖNMEZ G. M., CENGİZ SEVAL G., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.

50.Ulusal Hematoloji Kongresi, 29 October - 02 November 2024, (Full Text)

12. MANTLE HÜCRELİ LENFOMA TANILI HASTALARDA İBRUTİNİB KULLANIMI: TEK MERKEZ DENEYİMİ

KÖKCÜ G., CENGİZ SEVAL G., YÜKSEL M., TOPRAK S. K., ARSLAN Ö., ÖZCAN M., et al.

50.Ulusal Hematoloji Kongresi, 29 October - 02 November 2024, (Full Text)

13. GÜNCEL KLAVUZLAR EŞLİĞİNDE KLİNİKTE MASTOSİTOZ: TEK MERKEZ DENEYİMİ

AYDOĞAN M., CENGİZ SEVAL G., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.

50.Ulusal Hematoloji Kongresi, 29 October - 02 November 2024, (Full Text)

14. STEROİD REFRAKTER GRAFT VERSUS HOST HASTALIĞINDA FOTOFEREZ KULLANIMI VE YANITLARININ DEĞERLENDİRİLMESİ, TEK MERKEZ DENEYİMİ

BEKTAŞ M., ÇİFTÇİ A., CENGİZ SEVAL G., TOPRAK S. K., TOPÇUOĞLU P., ÖZCAN M., et al.

50.Ulusal Hematoloji Kongresi, 29 October - 02 November 2024, (Full Text)

15. HİPEREOZİNOFİLİK SENDROM ALT TİPLERİNDE TANI VE TEDAVİ: RETROSPEKTİF TEK MERKEZLİ ÇALIŞMA

BEKTAŞ M., ÇİFTÇİ A., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ÖZCAN M., et al.

50.Ulusal Hematoloji Kongresi, 29 October - 02 November 2024, (Full Text)

16. PAROKSİSMAL NOKTURNAL HEMOGLOBİNÜRİ TANILI HASTALARIN DEĞERLENDİRMESİ, TEK MERKEZLİ ÇALIŞMA

BEKTAŞ M., ÇİFTÇİ A., CENGİZ SEVAL G., YÜKSEL M., TOPÇUOĞLU P., ÖZCAN M., et al.

50.Ulusal Hematoloji Kongresi, 29 October - 02 November 2024, (Full Text)

17. MİKOSİZ FUNGOİDES VE SEZARY SENDROMLU HASTALARDA BRENTUXİMAB VEDOTİN TEDAVİSİNİN UZUN DÖNEM SONUÇLARI

SÖNMEZ G. M., ÖZSAN İ., DÜZ B., ŞANLI H., CENGİZ SEVAL G., DALVA K., et al.

50.Ulusal Hematoloji Kongresi, 29 October - 02 November 2024, (Full Text)

18. Prognostic evaluation of PET/CT in residual post-chemotherapy +/- RT masses in patients with Hodgkin Lymphoma and its impact on survival

BEKTAŞ M., KAR İ., CENGİZ SEVAL G., TOPRAK S. K., TOPÇUOĞLU P., ÖZCAN M., et al.

11TH AEGEAN HEMATOLOGY ONCOLOGY SYMPOSIUM, 19 - 22 September 2024, (Full Text)

19. ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN RELAPS/REFRACTORY LYMPHOMA PATIENTS: A SINGLE CENTER EXPERIENCE

Karakaya B., Yilmaz H., Ermis G. Y., Cengiz Seval G., Bozdag S. C., Toprak S. K., et al.

49th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, ELECTR NETWORK, 23 - 26 April 2023, pp.457-458, (Summary Text)

20. Allogeneic Stem Cell Transplantation for Relapsed and/or Refractory Hodgkin Lymphoma: A Multicenter Real World Experience

Koyun D., ŞAHİN U., CENGİZ SEVAL G., Sahin D. G., Gokmen A., Bozdag S. C., et al.

65th Annual Meeting of the American-Society-of-Hematology (ASH), California, United States Of America, 9 - 12 December 2023, vol.142, (Summary Text)

21. ALPHA-1-ANTITRYPSIN EXPERIENCE FOR STEROID-RESISTANT ACUTE GRAFT-VERSUS-HOST DISEASE

Koyun D., Cengiz Seval G., Bozdag S. C., Toprak S. K., Topçuoğlu P., Özcan M., et al.

49th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, ELECTR NETWORK, 23 - 26 April 2023, pp.301-302, (Summary Text)

22. EXTERNAL VALIDATION OF THREE EXISTING EARLY MYELOMA RELAPSE SCORES (BY EBMT, CIBMTR, AND GIMEMA) IN A SINGLE CENTER SHOWS MAJOR DIFFERENCES

Beksaç M., Cengiz Seval G., Civriz Bozdağ S., Toprak S. K., Yüksel M., Topçuoğlu P., et al.

The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians, Paris, France, 23 April 2023, vol.58, pp.107, (Full Text)

23. P19 EXTERNAL VALIDATION OF THREE EXISTING EARLY MYELOMA RELAPSE SCORES (BY EBMT, CIBMTR, AND GIMEMA) IN A SINGLE CENTER SHOWS MAJOR DIFFERENCES

BEKSAÇ M., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., et al.

The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation, France, 23 April 2023, (Full Text)

24. The Impact of CD34+Cell and Immunefector Cell Dose on Transplant Outcomes

Koyun D., Cengiz Seval G., Bozdag S. C., Toprak S. K., Topçuoğlu P., Özcan M., et al.

64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Louisiana, United States Of America, 10 - 13 December 2022, vol.140, pp.12673-12674, (Summary Text)

25. The efficacy and safety of second allogeneic hematopoietic stem cell transplantation

TOPRAK S. K., KIRCALİ E., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

2022 ASCO Annual Meeting, United States Of America, 01 June 2022, (Full Text)

26. Prophylactic defibrotide is effective for acute graft versus host disease as well as sinusoidal obstructive syndrome

KIRCALİ E., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), United States Of America, 19 - 22 March 2022, (Full Text)

27. Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia: A single center experience

İLHAN O., YAVUZ G., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

48th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), United States Of America, 19 - 22 March 2022, (Full Text)

28. İKİNCİ ALLOJENEİK KÖK HÜCRE NAKLİ: GERÇEK YAŞAM VERİSİ

KIRCALI E., CENGİZ SEVAL G., ÖZTÜRK C., YILMAZ H., Yavuz G., Karakaya B., et al.

14. Ulusal kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 10 March 2022, (Full Text)

29. GRAFT VERSUS HOST HASTALIĞI PROFİLAKSİSİNDE ATG VE POST CY KULLANIMININ NAKİL SONUÇLARINA ETKİSİ: TEK MERKEZ DENEYİMİ

Karakaya B., ŞAHİN Y. İ., MAMMADLI H., Yavuz G., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., et al.

14. Ulusal kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 10 March 2022, (Full Text)

30. THE OUTCOME OF AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION IN ELDERLY PATIENTS WITH AGGRESSIVE NON-HODGKIN LYPHOMA

İLHAN O., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., et al.

63TH ASH CONGRESS, ATLANTA, United States Of America, 8 - 11 December 2021, (Full Text)

31. The Outcome of Autologous Hematopoietic Cell Transplantation in Elderly Patients with Aggressive Non-Hodgkin Lymphoma

İLHAN O., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., et al.

63rd ASH Annual Meeting and Exposition, 11 December 2021, (Full Text)

32. AKUT PROMİYELOSİTİK LÖSEMİ TANILI HASTALARIN KLİNİK ÖZELLİKLERİ VE TEDAVİ SONUÇLARI: TEK MERKEZ DENEYİMİ

Yavuz Ermiş G., Yilmaz H., Özütemiz S., Selvi N., Öztürk C., Kırcalı E., et al.

47. Ulusal Hematoloji Kongresi , Antalya, Turkey, 4 - 07 November 2021, pp.202-204, (Full Text)

33. T/B LENFOBLASTİK LENFOMA TANILI HASTALARIN YENİ TEDAVİLER IŞIĞINDA RETROSPEKTİF DEĞERLENDİRİLMESİ

Karakaya B., Akbulut H., Öztürk C., Koyun D., Kırcalı E., Yilmaz H., et al.

47. Ulusal Hematoloji Kongresi , Antalya, Turkey, 4 - 07 November 2021, pp.178-179, (Full Text)

34. HODGKİN LENFOMA TANILI HASTALARDA EKSTRANODAL TUTULUM VE YENİ TEDAVİLER

Yavuz Ermiş G., Yilmaz H., Özütemiz S., Selvi N., Öztürk C., Kırcalı E., et al.

47. Ulusal Hematoloji Kongresi , Antalya, Turkey, 4 - 07 November 2021, pp.346-347, (Full Text)

35. PROFLAKTİK DEFİBROTİD SOS DIŞINDA AKUT GRAFT VS HOST HASTALIĞINDA DA ETKİN

KIRCALI E., CENGİZ SEVAL G., ÖZTÜRK C., YILMAZ H., Yavuz G., Karakaya B., et al.

47. Ulusal Hematoloji Kongresi, 04 November 2021, (Full Text)

36. RELAPS/ REFRAKTER HODGKİN LENFOMA HASTALARINDA ALLOJENİK HEMATOPOETİK KÖK HÜCRE NAKLİ: TEK MERKEZ DENEYİMİ

Koyun D., Şahin U., Cengiz Seval G., Civriz Bozdağ S., Toprak S. K., Yüksel M., et al.

13. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Turkey, 2 - 03 April 2021, no.52, pp.104-105, (Full Text)

37. ALLOJENİK KÖK HÜCRE NAKLİ HASTALARINDA PERİTRANSPLANT METRONİDAZOL KULLANIMIYLA AKUT GVHD RİSKİNİN İLİŞKİ

KIRCALI E., CENGİZ SEVAL G., ÖZTÜRK C., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

13. Ulusal kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 02 April 2021, (Full Text)

38. Allojenik Kök Hücre Nakli Hastalarında Peritransplant Metronidazol Kullanımıyla Akut GVHD Riskinin İlişkisi

KIRCALİ E., SEVAL G. C., Öztürk C., CİVRİZ BOZDAĞ S., YÜKSEL M. K., TOPÇUOĞLU P., et al.

13. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 2 - 03 April 2021, (Full Text)

39. Relaps/Refrakter Hodgkin Lenfoma Hastalarında Allojenik Hematopoetik Kök Hücre Nakli: Tek Merkez Deneyimi

KOYUN D., ŞAHİN U., SEVAL G. C., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M. K., et al.

13. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 2 - 03 April 2021, (Full Text)

40. Solid Organ Nakli Ve Allojenik Kök Hücre Nakli Sonrası Gelişen Post-Transplant Lenfoproliferatif Hastalık- Tek Merkez Deneyimi

Öztürk C., KIRCALİ E., KOYUN D., YILMAZ H., YAVUZ G., KARAKAYA B., et al.

13. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 2 - 03 April 2021, (Full Text)

41. MULTİPL MİYELOMDA OTOLOG PRİFERİK KÖK HÜCRE NAKLİ SONRASI ERKEN NÜKSÜ BELİRLEMEDE CIBMTR, ISS VE R-ISS SKORLAMA SİSTEMLERİNİN KARŞILAŞTIRILMASI

CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

13. Ulusal kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 02 April 2021, (Full Text)

42. THE IMPACT OF PRETRANSPLANT IMMUNOMODULATORY DRUGS ON CMV REACTIVATION

YÜKSEL M., CENGİZ SEVAL G., USLU A., KIRCALI E., KOYUN D., Yavuz G., et al.

8 45 th International Congress on Leukemia Lymphoma Myeloma, Ankara, Turkey, 21 May 2021, vol.38, no.71, pp.1-81, (Full Text)

43. The impact of pretransplant ımmunomodulatory drugs on cmv reactıvatıon

YÜKSEL M., CENGİZ SEVAL G., USLU A., KIRCALI E., KOYUN D., YAVUZ G., et al.

8th International congress on leukemia lymphoma myeloma, 2021, 21 May 2021, (Full Text)

44. Comparative Analysis and Validation of CIBMTR Early Relapse Risk Score with ISS and R-ISS: Single Center Experience from Ankara University

SEVAL G. C., BOZDAĞ S., TOPRAK S. K., YÜKSEL M. K., TOPÇUOĞLU P., ARSLAN Ö., et al.

Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR, 08 February 2021, (Full Text)

45. Impact of Peritransplant Metronidazole Use on Acute Graft Versus Host Disease in Allogeneic Hematopoietic Transplant Patients

KIRCALİ E., SEVAL G. C., ÖZTÜRK C., BOZDAĞ S., YÜKSEL M. K., TOPÇUOĞLU P., et al.

Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR, 8 - 12 February 2021, (Full Text)

46. GRAFT VS HOST HASTALIĞINDA ALFA- 1 ANTİTRİPSİN DENEYİMİMİZ

Koyun D., Cengiz Seval G., Kırcalı E., Civriz Bozdağ S., Toprak S. K., Topçuoğlu P., et al.

46. Ulusal Hematoloji Kongresi , Antalya, Turkey, 28 - 31 October 2020, no.283, pp.117-118, (Full Text)

47. FOLİKÜLER LENFOMADA BAZAL PET’ TE TOPLAM METABOLİK TÜMÖR HACMİ VE TOPLAM LEZYON GLİKOLİZİNİN PROGNOSTİK ÖNEMİ

Kırcalı E., Cengiz Seval G., Araz M., Uslu A., Öztürk C., Koyun D., et al.

46. Ulusal Hematoloji Kongresi, Antalya, Turkey, 28 - 31 October 2020, no.278, pp.105, (Full Text)

48. AKUT MYELOBLASTİK LÖSEMİ HASTALARINDA NÜKLEOFOSMİN MUTASYONU MİNİMAL REZİDÜEL HASTALIK TAKİBİNDE YOL GÖSTERİCİMİDİR

CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., DEMİRER T., BEKSAÇ M., CİVRİZ BOZDAĞ S., et al.

42.Ulusal Hematoloji Kongresi, Turkey, 28 - 30 October 2020, (Full Text)

49. Foliküler lenfomada bazal PET'te toplam metabolik tümör hacmi ve toplan lezyon glikolizinin prognostik önemi.

CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., DEMİRER T., BEKSAÇ M., ÖZKAN E., et al.

46. Ulusal Hematoloji Kongresi, Turkey, 28 - 31 October 2020, (Full Text)

50. The Influence Of Antı-Thymocyte Globulın (Atg) On The Outcomes Of Patıents Wıth Aml W/Wo Measurable Resıdual Dısease (Mrd) At The Tıme Of Unrelated Donor Transplantatıon

CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., KIRCALİ E., BALTACI M. A., TOPÇUOĞLU P., et al.

46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 29 August - 01 September 2020, (Full Text)

51. Flamsa-Based Hıgh-Dose Sequentıal Condıtıonıng Regımen Followed By Allogeneıc Hematopoıetıc Stem Cell Transplantatıon (Allo-Hsct): Is It Effectıveın Patıents Wıth Prımary Refractory Or Relapsed Acute Leukemıa?

CENGİZ SEVAL G., EKİN K., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., ARSLAN Ö., et al.

46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 29 August - 01 September 2020, (Full Text)

52. Role Of Chımerısm And Flow-Cytometrıc Monıtorıng Of Measurable Resıdualdısease (Mrd) After Allogeneıc Hematopoıetıc Stem Cell Transplantatıon (Allohsct) In Predıctıng Relapse In Acute Myeloıd Leukemıa (AML)

CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., DALVA K., et al.

46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT, 29 August - 01 September 2020, (Full Text)

53. Treatment Of Thrombocytopenıa After Allogeneıc Stem Cell Transplantatıonwıth Eltrombopag

KIRCALİ E., CENGİZ SEVAL G., KOYUN D., ÖZTÜRK C., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 29 August - 01 September 2020, (Full Text)

54. Allogeneic hematopoietic stem cell transplantation for primary myelofibrosis: A single-center experience.

Demirer T., Seval G. C., Bozdag S. C., Toprak S. K., Yuksel M. K., Topcuoglu P., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 - 31 May 2020, vol.38, (Summary Text)

55. HEMORAJİK SİSTİT İÇİN YARGILANAN SİKLOFOSFAMİD SUÇSUZ BULUNDU: TEK MERKEZ 7 YILLIK DENEYİM

CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., DEMİRER T., BEKSAÇ M., CİVRİZ BOZDAĞ S., et al.

12. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Turkey, 5 - 07 March 2020, (Full Text)

56. AML TANISI İLE AKRABA DIŞI VERİCİDEN AHKHN YAPILAN HASTALARDA ATG KULLANIMININ NAKİL SONUÇLARINA ETKİSİ

CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., DEMİRER T., BEKSAÇ M., CİVRİZ BOZDAĞ S., et al.

12. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Turkey, 5 - 07 March 2020, (Full Text)

57. CD34 VE İMMUNEFEKTÖR HÜCRE SAYIMININ TRANSPLANTASYON SONUÇLARINA ETKİSİ

CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., DEMİRER T., BEKSAÇ M., CİVRİZ BOZDAĞ S., et al.

12. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Turkey, 5 - 07 March 2020, (Full Text)

58. CD34+ VE İMMUNEFEKTÖR HÜCRE SAYIMININ TRANSPLANTASYON SONUÇLARINA ETKİSİ

Koyun D., Cengiz Seval G., Dalva K., Uslu A., Öztürk C., Kırcalı E., et al.

12. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Muğla, Turkey, 5 - 07 March 2020, no.159, pp.60-61, (Full Text)

59. Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis

CENGİZ SEVAL G., ÖZTÜRK N., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR 2020, 19 - 23 February 2020, (Full Text)

60. Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow

CENGİZ SEVAL G., USLU A., KIRCALİ E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.

Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, 19 - 23 February 2020, (Full Text)

61. Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis

SEVAL G. C., Öztürk n., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

61st ASH Annual Meeting, 7 - 10 December 2019, (Full Text)

62. Effect of Cyclophosphamide on Hemorrhagic Cystitis Following Haploidentical Related Compared to Matched Related/Unrelated Donor Hematopoietic Stem Cell Transplantation: A 7-Year Tertiary Center Analysis

CENGİZ SEVAL G., Ozturk N., CİVRİZ BOZDAĞ S., Yuksel M. K., TOPÇUOĞLU P., ARSLAN Ö., et al.

61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Florida, United States Of America, 7 - 10 December 2019, vol.134, (Summary Text)

63. Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data

CENGİZ SEVAL G., Uslu A., Kircali E., CİVRİZ BOZDAĞ S., DALVA K., TOPRAK S. K., et al.

61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Florida, United States Of America, 7 - 10 December 2019, vol.134, (Summary Text)

64. Which One, Generic Vs Original Glivec Is More Effective in Patients with Chronic Myeloid Leukemia?

Kircali E., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., Yuksel M. K., ARSLAN Ö., et al.

61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Florida, United States Of America, 7 - 10 December 2019, vol.134, (Summary Text)

65. YENİ TANI KLL HASTALARINDA TANI SIRASINDAKİ CD49DEKSPRESYONUNUN HASTALIĞA OZGU BAŞKA PARAMETRELERLEİLİŞKİSİ

TOPRAK S. K., güven m., CENGİZ SEVAL G., DALVA K., İpek Ş., Okul N., et al.

45. ULUSAL HEMATOLOJİ KONGRESİ, Turkey, 30 October - 02 November 2019, (Summary Text)

66. HANGİSİ, ORJİNAL İMATİNİB Mİ JENERİK Mİ KRONİK MYELOİD LÖSEMİDE DAHA ETKİN?

KIRCALI E., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., ARSLAN Ö., et al.

45. Ulusal Hematoloji Kongresi, 31 October 2019, (Full Text)

67. KRONİK MİYELOİD LOSEMİ (KML) HASTALARINDA KML KOKHUCRESİ BCR- ABL’DEN BAĞIMSIZ PROGNOSTİK BİR FAKTOR OLABİLİR Mİ?

TOPRAK S. K., güven m., CENGİZ SEVAL G., DALVA K., İpek Ş., Okul N., et al.

45. ULUSAL HEMATOLOJİ KONGRESİ, Turkey, 30 October - 02 November 2019, (Summary Text)

68. Negative Impact of High LDH at Diagnosis on OS, But Not PFS, Can Be Overcome by Autologous Stem Cell Transplantation

CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

17th International Myeloma Workshop, 12 - 15 September 2019, (Full Text)

69. Haploidentical stem cell transplantation may be an option for hematological malignancies in urgent conditions

İLHAN O., CENGİZ SEVAL G., Uslu A., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.

45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Germany, 24 - 27 March 2019, vol.54, pp.382, (Summary Text)

70. Is mobilization with chemotherapy effect response in the multiple myeloma?

CENGİZ SEVAL G., Uslu A., CİVRİZ BOZDAĞ S., YÜKSEL M., ARSLAN Ö., ÖZCAN M., et al.

45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Germany, 24 - 27 March 2019, vol.54, pp.500, (Summary Text)

71. Can the drugs used before autologous hematopoietic stem cell transplantation have impact on CMV reactivation that results in decreased os in myeloma patients after ASCT?

YÜKSEL M., CENGİZ SEVAL G., Uslu A., Kircili E., KOYUN D., Ozturk C., et al.

45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Germany, 24 - 27 March 2019, vol.54, pp.505-506, (Summary Text)

72. Can Nelarabıne Rescue The Graft After Allogeneıc Hematopoıetıc Stem Cell Transplantatıon In T-All ?

YÜKSEL M., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., et al.

24 Congress of the European Hematology Association, 13 - 16 June 2019, (Summary Text)

73. SUCCESSFUL TREATMENT OF GRAFT FAILURE WITH SECOND ALLOGENEIC STEM CELL TRANSPLANTATION WITHOUT CONDITIONING REGIMEN

Cengiz Seval G., Uslu A., Öztürk C., Civriz Bozdağ S., Yüksel M., Topçuoğlu P., et al.

8th International Congress on Leukemia Lymphoma Myeloma, İstanbul, Turkey, 2 - 04 May 2019, pp.75, (Full Text)

74. CAN THE DRUGS USED BEFORE AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (ASCT) HAVE IMPACT ON CMV REACTIVATION THAT RESULTS IN DECREASED OS IN MYELOMA PATIENTS AFTER ASCT?

Yüksel M., Cengiz Seval G., Uslu A., Kırcalı E., Koyun D., Öztürk C., et al.

7th International Congress on Leukemia Lymphoma Myeloma, İstanbul, Turkey, 2 - 04 May 2019, pp.59, (Full Text)

75. IS AGE AN IMPORTANT FACTOR FOR AUTOLOGOUS PERIPHERAL HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS WITH NONHODGKIN LYMPHOMA?

Cengiz Seval G., Uslu A., Civriz Bozdağ S., Toprak S. K., Yüksel M., Topçuoğlu P., et al.

7th International Congress on Leukemia Lymphoma Myeloma, İstanbul, Turkey, 2 - 04 May 2019, pp.47-48, (Full Text)

76. LEUKAPHERESIS REDUCES 4-WEEK MORTALITY IN ACUTE MYELOID LEUKEMIA PATIENTS WITH HYPERLEUKOCYTOSIS - A RETROSPECTIVE STUDY FROM A TERTIARY CENTER

Cengiz Seval G., Uslu A., Civriz Bozdağ S., Toprak S. K., Yüksel M., Topçuoğlu P., et al.

7th International Congress on Leukemia Lymphoma Myeloma, İstanbul, Turkey, 2 - 04 May 2019, pp.37, (Full Text)

77. HAPLOIDENTICAL STEM CELL TRANSPLANTATION MAY BE A GOOD ALTERNATIVE AS SALVAGE TREATMENT FOR HEAVILY PRETREATED PATIENTS WITH LEUKEMIA

Cengiz Seval G., Uslu A., Civriz Bozdağ S., Toprak S. K., Yüksel M., Topçuoğlu P., et al.

7th International Congress on Leukemia Lymphoma Myeloma, İstanbul, Turkey, 2 - 04 May 2019, pp.56-57, (Full Text)

78. CAN AUTOLOGOUS STEM CELL TRANSPLANTATION ABROGATE THE POOR PROGNOSIS ASSOCIATED WITH HIGH LDH?

Cengiz Seval G., Civriz Bozdağ S., Yüksel M., Topçuoğlu P., Arslan Ö., Özcan M., et al.

7th International Congress on Leukemia Lymphoma Myeloma, İstanbul, Turkey, 2 - 04 May 2019, pp.45, (Full Text)

79. Pretransplant hemoglobin and serum creatinine levels correlate with progression free survival in myeloma patients undergoing autologous stem cell transplantation.

DEMİRER T., CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37, (Summary Text)

80. Can autologous stem cell transplantation abrogate the poor prognosis associated with high LDH in myeloma patients?

Ilhan O., CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., Topcuoglu P., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37, (Summary Text)

81. CAN AUTOLOGOUS STEM CELL TRANSPLANTATIONABROGATE THE POOR PROGNOSIS ASSOCIATED WITH HIGHLDH?

SEVAL G. C., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.

7th International Congress on Leukemia Lymphoma Myeloma, 2 - 04 May 2019, (Full Text)

82. retrospective analysis of 149 unselected patıents wıth mantle cell lymphoma confırms prognostic relevance of mıpı: sıngle center ecperıence

CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.

ICLLM 2019, 02 May 2019, (Full Text)

83. CAN ELTROMBOPAG TREAT THE THROMBCYTOPENIA AFTER STEM CELL TRANSPLANTATION

Yüksel M., Kırcalı E., Cengiz Seval G., Koyun D., Uslu A., Öztürk C., et al.

7th International Congress on Leukemia Lymphoma, İstanbul, Turkey, 2 - 04 May 2019, (Full Text)

84. MULTİPLE MYELOM HASTALARINDA OTOLOG PERİFERİK KÖK HÜCRE NAKLİ ESNASINDA GELİŞEN NÖTROPENİK ATEŞ

Uslu A., Cengiz Seval G., Öztürk C., Narlı Özdemir Z., Kırcalı E., Koyun D., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Turkey, 1 - 02 March 2019, no.142, pp.130, (Full Text)

85. Allojeneik Kök Hücre Nakli Sonrası Akut Lösemi Hastalarında Nüksü Öngörmede Kimerizm İle Mrd Karşılaştırılması

CENGİZ SEVAL G., ULAŞ B. B., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Turkey, 1 - 03 March 2019, (Summary Text)

86. İyi Riskli Aml’de İkinci Tam Remisyonda Allojeneik Hematopoietik Kök Hücre Nakli Tek Merkez Deneyimi

PEKCAN G., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Turkey, 1 - 03 March 2019, (Summary Text)

87. Miyelom Hastalarında Ohkhn Öncesi Kullanılan İlaçların Cmv Reaktivasyonu Üzerine Sağkalımı Azaltıcı Etkisi Olabilir mi?

YÜKSEL M., CENGİZ SEVAL G., USLU A., KIRCALİ E., KOYUN D., ÖZTÜRK C., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Turkey, 1 - 03 March 2019, (Summary Text)

88. Posttransplant Lenfositoz Önemli Bir Parametre midir?

CENGİZ SEVAL G., USLU A., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Turkey, 1 - 03 March 2019, (Summary Text)

89. Transplant Sonrası Trombositopenide Eltrombopag: Tek Merkez Deneyimimiz

Kırcali E., Cengiz Seval G., Koyun D., Civriz Bozdağ S., Topçuoğlu P., Özcan M., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Turkey, 1 - 03 March 2019, (Full Text)

90. T-All Hastalarında Allojeneik Hematopoetik Kök Hücre Nakli Sonrasında Nelarabin Tedavisi Graftı Kurtarabilir mi?

CENGİZ SEVAL G., USLU A., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Turkey, 1 - 03 March 2019, (Summary Text)

91. Refrakter Akut Lösemili Hastalarda Ardışık Kurtarma Tedavisi İle Birlikte Ahkhn Yeterli Kür Sağlayabilir mi?

CENGİZ SEVAL G., KIRCALİ E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., ARSLAN Ö., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Turkey, 1 - 03 March 2019, (Summary Text)

92. CAN AUTOLOGOUS STEM CELL TRANSPLANTATIONABROGATE THE POOR PROGNOSIS ASSOCIATED WITH HIGH LDH?

CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.

7th International Congress on Leukemia Lymphoma Myeloma, 3 - 04 May 2019, (Full Text)

93. LEUKAPHERESIS REDUCES 4-WEEK MORTALITY IN ACUTEMYELOID LEUKEMIA PATIENTS WITH HYPERLEUKOCYTOSIS - A RETROSPECTIVE STUDY FROM A TERTIARY CENTER

CENGİZ SEVAL G., USLU A., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., et al.

7th International Congress on Leukemia Lymphoma Myeloma, 3 - 04 May 2019, (Full Text)

94. MİYELOM HASTALARINDA OHKHN ÖNCESİ KULLANILANİLAÇLARIN CMV REAKTİVASYONU ÜZERİNE SAĞKALIMIAZALTICI ETKİSİ OLABİLİR Mİ?

YÜKSEL M., CENGİZ SEVAL G., USLU A., KIRCALI E., KOYUN D., ÖZTÜRK C., et al.

11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Turkey, 1 - 03 March 2019, (Summary Text)

95. Influence of Conditioning Regimens with Total Body Irradiation (TBI) on Graft Versus Host Disease and Graft Versus Leukemia Effect Following Donor Lymphocyte Infusions (DLI)

CENGİZ SEVAL G., Atilla E., Ulas B., CİVRİZ BOZDAĞ S., TOPRAK S. K., Yuksel M. K., et al.

Transplant and Cell Therapy Meeting / Combined Annual Meetings of the American-Society-for-Blood-and-Marrow-Transplantation (ASBMT) and the Center-for-International-Blood-and-Marrow-Transplant-Research (CIBMTR), Texas, United States Of America, 13 - 24 February 2019, vol.25, (Summary Text)

96. İmmun Trombositopeni (İTP) hastalarında ABO kan gruplarının birinci basamak tedavi yanıtına etkisi

AKKUŞ E., FİDAN Ç., KUŞTAŞ A. A., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

TKBD Uluslararası Katılımlı Hematolojik Hastalıkların Tanı Ve İzleminde Laboratuvar Sempozyumu, Turkey, 5 - 07 April 2018, vol.16, pp.44, (Summary Text)

97. Comparision of Outcomes According to HLA Disparity in Acute Leukemia Patients: A Single Cente Institution Experience

TOPÇUOĞLU P., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., DALVA K., et al.

60th ASH Annual Meeting and Exposition, 01 December 2018, (Full Text)

98. Comparision of Outcomes According to HLA Disparity in Acute Leukemia Patients: A Single Center Institution Experience

TOPÇUOĞLU P., SEVAL G. C., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., DALVA K., et al.

60th ASH Annual Meeting, san diego, United States Of America, 29 November - 05 December 2018, vol.132, pp.4673, (Full Text)

99. Impact of ABO Mismatch on Outcomes of Allogeneic Hematopoietic Stem Cell Recipients: 30 Years of Experience with 1016 Patients

Atilla E., TOPÇUOĞLU P., AKKUŞ E., Atilla P. A., CİVRİZ BOZDAĞ S., YÜKSEL M., et al.

60th Annual Meeting of the American-Society-of-Hematology (ASH), California, United States Of America, 1 - 04 December 2018, vol.132, (Summary Text)

100. Donor Lymphocyte Infusions for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation: Single Center Experience

GÜRMAN G., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., et al.

60th Annual Meeting of the American-Society-of-Hematology (ASH), California, United States Of America, 1 - 04 December 2018, vol.132, (Summary Text)

101. Akut Miyeloid Lösemide Nakil Öncesi ve Nakil Sonrası +28. Gün Değerlendirilen Minimal Kalıntı Hastalığın Hastalık Seyrine Etkisi

DALVA K., NARLI ÖZDEMİR Z., ŞAHİN U., USLU A., MURADOVA B., CENGİZ SEVAL G., et al.

44. Ulusal Hematoloji Kongresi, Antalya, Turkey, 31 October - 03 November 2018, pp.245-246, (Summary Text)

102. ALLOJENİK HEMATOPOİETİK KÖK HÜCRE NAKLİ YAPILAN ALL HASTALARINDA CMV ENFEKSİYONUNUN NAKİL SONUÇLARINA ETKİLERİ

KALACI E., ŞAHİN EROĞLU D., CENGİZ SEVAL G., NARLI ÖZDEMİR Z., BEKSAÇ M., ÖZCAN M., et al.

44. Ulusal Hematoloji Kongresi, Turkey, 31 October - 03 November 2018, (Full Text)

103. ALLOJENİK HEMATOPOİETİK KÖK HÜCRE NAKLİ YAPILANALL HASTALARINDA CMV ENFEKSİYONUNUN NAKİLSONUÇLARINA ETKİLERİ

KALACI E., ŞAHİN EROĞLU D., CENGİZ SEVAL G., NARLI ÖZDEMİR Z., BEKSAÇ M., ÖZCAN M., et al.

44. Ulusal Hematoloji Kongresi, Turkey, 31 October - 03 November 2018, (Summary Text)

104. AKUT LÖSEMİ HASTALARINDA HLA UYUŞUMSUZLUĞUNUNNAKİL SONUÇLARINA ETKİSİ: TEK MERKEZ DENEYİMİ

CENGİZ SEVAL G., NARLI ÖZDEMİR Z., TATAR L., SÖKMEN M., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

44. Ulusal Hematoloji Kongresi, Turkey, 31 October - 03 November 2018, (Summary Text)

105. Fit Elderly Patients with aggressive lymphoma do not need dose reduction of conditioning regimen

Ilhan O., CENGİZ SEVAL G., Uslu A., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.

44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portugal, 18 - 21 March 2018, vol.53, pp.272-273, (Summary Text)

106. The Outcome of Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation for Isolated CD4 (+) T-cell Deficiency with Interleukin-2 Inducible T-cell Kinase (ITK) Gene Defect

YÜKSEL M., Ozdemir Z. N., Sahin U., ÇAĞDAŞ AYVAZ D. N., Atikcan D. T., Sertesen E., et al.

44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portugal, 18 - 21 March 2018, vol.53, pp.533-534, (Summary Text)

107. Impact of Hepatitis B Core Antibody Seopositivity on the Liver Function Tests after Autologous Hematopoietic Stem Cell Transplantation For Multiple Myeloma

CENGİZ SEVAL G., Sertesen E., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., Aslan O., et al.

44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portugal, 18 - 21 March 2018, vol.53, pp.338, (Summary Text) Sustainable Development

108. Donor lymphocyte infusion after salvage chemotherapy in relapsed acute myeloblastic leukemia patients after allogeneic stem cell transplantation

Uslu A., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., GÜRMAN G., Demirer T., Arslan O., et al.

44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portugal, 18 - 21 March 2018, vol.53, pp.161-162, (Summary Text)

109. Is post-transplant albumin a predictor of early transplant complications?

TOPÇUOĞLU P., CENGİZ SEVAL G., AKKUŞ E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.

44th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Lisbon, Portugal, 18 - 21 March 2018, vol.53, pp.344-345, (Summary Text)

110. Retrospective analysis of 115 unselected patients with mantle cell lymphoma: Single center experience

Cengiz Seval G., BULAT B., Ozel F., Tasci O., Kuzu I., CİVRİZ BOZDAĞ S., et al.

ASCO Annual Meeting 2018, 1 - 05 June 2018, vol.36, pp.19525, (Full Text)

111. ALLOJENEİK KÖK HÜCRE NAKLİ SONRASI GELİŞENKARACİĞER SİNÜZOİDAL TIKANIKLIK SENDROM İNSİDANSIVE KLİNİK BULGULAR

GÜNDÜZ M., ATİLLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., ARSLAN Ö., et al.

10. ULUSAL KEMİK İLİĞİTRANSPLANTASYONU VEHÜCRESEL TEDAVİLER KONGRESİ, Antalya, Turkey, 1 - 03 March 2018, (Summary Text)

112. Allojeneik Hematopoetik Kök Hücre Nakli Sonrası Akut Myeloid Lösemi Nüksünün Yönetimi ve Prognozu

ŞAHİN U., GÜNDÜZ M., MERTER M., NARLI ÖZDEMİR Z., ÖZEN M., CİVRİZ BOZDAĞ S., et al.

10. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Turkey, 1 - 03 March 2018, pp.126-127, (Summary Text)

113. KEMOTERAPİ İLE MOBİLİZASYON MULTİPL MİYELOMDA YANITLARI ETKİLİYOR MU?

CENGİZ SEVAL G., USLU A., CİVRİZ BOZDAĞ S., YÜKSEL M., ARSLAN Ö., ÖZCAN M., et al.

10. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 01 March 2018, (Full Text)

114. MYELOFİBROZİSTE ALLOJENEİK HEMATOPOETİK KÖK HÜCRE NAKLİ SONUÇLARI: TEK MERKEZ DENEYİMİ

CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

10. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 01 March 2018, (Full Text)

115. Ph Negatif ALL’de 1. Tam Remisyonda Yapılan Pekiştirme Tedavileri Nakil Sonrası Başarıyı Arttırır

NARLI ÖZDEMİR Z., ŞAHİN U., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., et al.

10. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Turkey, 1 - 03 March 2018, (Summary Text)

116. Age is Not an Important Factor for Autologous Peripheral Hematopoietic Stem Cell Mobilization and Collection in Patients with Multiple Myeloma

İLHAN O., CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

Blood and Marrow Transplantion Tandem Meetings of the Center-for-International-Blood-and-Marrow-Transplant-Research (CIBMTR) / American-Society-for-Blood-and-Marrow-Transplantation (ASBMT), Utah, United States Of America, 21 - 25 February 2018, vol.24, (Summary Text)

117. ITK Gen Defektine Bağlı CD4+ T Hücre Yetmezliği Olan Erişkinde Allojeneik Hematopoietik Kök Hücre Naklinin Sonuçları

YÜKSEL M., NARLI ÖZDEMİR Z., ŞAHİN U., CENGİZ SEVAL G., ÇAĞDAŞ AYVAZ D., ATİKCAN D. T., et al.

10. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Turkey, 01 March 2018, pp.138, (Summary Text)

118. AKUT GRAFT VERSUS HOST HASTALIĞI KLİNİK SONUÇLARI: TEK MERKEZ DENEYİMİ

NARLI ÖZDEMİR Z., CENGİZ SEVAL G., USLU A., ÖZTÜRK C., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

10. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Antalya, Turkey, 01 March 2018, (Summary Text)

119. Age Is Not Important for Autologous Peripheral Hematopoietic Stem Cell Transplantation in Multiple Myeloma

Ilhan O., CENGİZ SEVAL G., TOPRAK S. K., Topcuoglu P., Ozel F., CİVRİZ BOZDAĞ S., et al.

59th Annual Meeting of the American-Society-of-Hematology (ASH), Georgia, United States Of America, 9 - 12 December 2017, vol.130, (Summary Text)

120. Dilemma-High Response Rates Vs High Toxicity: Autologous Stem Cell Transplantation for Lymphoma

Atilla E., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., Topcuoglu P., Akan H., et al.

59th Annual Meeting of the American-Society-of-Hematology (ASH), Georgia, United States Of America, 9 - 12 December 2017, vol.130, (Summary Text)

121. Engrafmanın Erken Belirteci: Büyük Boyanmamış Hücreler

Aydın T., MERTER M., ŞAHİN U., Pekcan G., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., et al.

43. Ulusal Hematoloji Kongresi, Antalya, Turkey, 1 - 04 November 2017, pp.53, (Summary Text)

122. İmmun Trombositopenide (İTP) Yenilikler Işığında Klinik Retrospektif Değerlendirme: Tek Merkez Deneyimi

AKKUŞ E., KUŞTAŞ A. A., Pekcan G., MERTER M., ŞAHİN U., CİVRİZ BOZDAĞ S., et al.

43. Ulusal Hematoloji Kongresi, Antalya, Turkey, 1 - 04 November 2017, pp.98-99, (Summary Text)

123. OTOLOG PERİFERİK KÖK HÜCRE NAKLİNDE KÖK HÜCRESAKLANMA SÜRESİ ENGRAFMAN SÜRESİNİ ETKİLER Mİ?

MERTER M., Güleç B., Özcan G., Zehra Özdemir Z., CİVRİZ BOZDAĞ S., YÜKSEL M., et al.

43. Ulusal Hematoloji Kongresi, Antalya, Turkey, 1 - 04 November 2017, pp.220, (Summary Text)

124. peripheral blood stem cell mobilization and collection from elderly patients with multiple myeloma:A single center experience

seval G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

ebmt 2017, 26 - 29 March 2017, (Summary Text)

125. Autologous Stem Cell Trnasplantation for Mantle Cell Lymphoma: A Single Center Exprience

TOPRAK S. K., ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

Exprience22nd Congress of the European Hematolgy Association, 22 June - 25 May 2017, (Summary Text)

126. Allojeneik stem cell transplantation results in our myelodysplastic sydrome (MDS) patientes

GÜRMAN G., ATACA ATİLLA P., AYDIN T., ATİLLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

patientes53rd Annual Meeting Jun 2-6, 2017, 2 - 06 June 2017, (Summary Text)

127. Comparison of myeloablative vs reduced intensity conditioning regimens in stem cell transplantationd for acute myeloid leukemia

GÜRMAN G., AYDEMİR GULOKSUZ G., ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., et al.

leukemia53rd Annual Meeting, 2 - 06 June 2017, (Summary Text)

128. Large Unstained Cell Percentage as a Predictor of Efficacious Peripheral Stem Cell Mobilization

MERTER M., KÖKEN K., YÜKSEL M., NURDAN DEMİR E., ŞAHİN U., CİVRİZ BOZDAĞ S., et al.

6th International Congress on Leukemia Lymphoma Myeloma, 11 - 13 May 2017, (Summary Text)

129. A biosimilar G-CSF filgrastim is as effective as a reference drug, however, it is not as cost effective as it supposed to be

PEKCAN G., YÜKSEL M., ŞAHİN U., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., et al.

6th International Congress on Leukemia Lymphoma Myeloma, Antalya, Turkey, 11 - 13 May 2017, pp.112, (Summary Text)

130. A single center experience with two decades of follow-up on patients with hairy cell leukemia.

İLHAN O., Atilla E., Atilla P. A., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., et al.

53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, United States Of America, 2 - 07 June 2017, vol.35, (Summary Text)

131. Comparison of myeloablative vs reduced intensity conditioning regimens in stem cell transplantations for acute myeloid leukemia.

GÜRMAN G., Guloksuz G. A., Atilla E., Atilla P. A., CİVRİZ BOZDAĞ S., YÜKSEL M., et al.

132. Peripheral blood stem cell mobilization and collection from elderly patients (265 years) with multiple myeloma: A single center experience

CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

43rd Annual Meeting of the European Society for Blood and Marrow Transplantation, 26 March 2017, (Full Text)

133. Herpes SimplexVirus infection in patients after allogeneic hematopoetic stem cell transplantation

ATİLLA E., ÖZEL F., YILMAZ V., ATACA ATİLLA P., ATEŞAĞAOĞLU B., CİVRİZ BOZDAĞ S., et al.

43rd Annual Meeting Of EBMT, 26 - 29 March 2017, (Summary Text)

134. Acute GVHD and unreated/haploidentical Trnasplants incrreses the incidence of hemorrhagic cystitis in Allo- HSCT Recipients

TOPÇUOĞLU P., ATİLLA E., ATACA ATİLLA P., USLU A., CİVRİZ BOZDAĞ S., YÜKSEL M., et al.

43rd Annual Meeting Of EBMT, 26 - 29 March 2017, (Summary Text)

135. Large Unsatained Cell (LUC) percentage as a predictor of efficacious peripheral stem cell mobilization in autologous stem cell transplantation

MERTER M., KÖKEN K., YÜKSEL M., DEMİR N., ŞAHİN U., CİVRİZ BOZDAĞ S., et al.

43rd Annual Meeting of the European Society for Blood and Marrow Transplantation, 26 - 29 March 2017, (Summary Text)

136. Evalauting peritransplant albümin decline as a predictor os acute graft versus host disease

MERTER M., YÜKSEL M., NURDAN DEMİR E., ŞAHİN U., CİVRİZ BOZDAĞ S., TOPÇUOĞLU P., et al.

43rdAnnual Meeting of the European Society for Blood and Marrow Transplantation, 26 - 29 March 2017, (Summary Text)

137. Catheter Thrombosis in Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) Recipients

GÜRMAN G., ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., et al.

BMT Tandem Meetings, 22 - 26 February 2017, (Summary Text)

138. Comparison of Reduced Intensity Conditioning (RIC) Regimen in Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) for Adult Patients with Acute Leukemia

GÜRMAN G., gülöksüz g., ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., et al.

58th ASH, 3 - 06 December 2016, vol.128, (Summary Text)

139. Comparison of Reduced Intensity Conditioning (RIC) Regimen and Myeloablative Conditioning (MAC) Regimen in Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) for Adult Patients with Acute Leukemia

GÜRMAN G., Guloksuz G. A., Atilla E., Atilla P. A., CİVRİZ BOZDAĞ S., YÜKSEL M., et al.

58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), California, United States Of America, 3 - 06 December 2016, vol.128, (Summary Text)

140. TROMBOTİK MİKROANJİOPATİDE TERAPÖTİKPLAZMA DEĞİŞİMİ

ATİLLA E., ATACA ATİLLA P., TOPRAK S. K., TOPÇUOĞLU P., YÜKSEL M., CİVRİZ BOZDAĞ S., et al.

42. Ulusal Hematoloji, Turkey, 19 - 22 October 2016

141. ANTİ HLA ANTİKOR VARLIĞININ ALLOJENEİK KÖKHÜCRE NAKLİ YAPILAN HASTALARDA ENGRAFMANÜZERİNE ETKİSİ TEK MERKEZ DENEYİMİ

MERTER M., AYDOĞAN M., TEKEŞ M. A., ŞAHİN U., AYYILDIZ Ö. M., KOCABAY H. E., et al.

42. Ulusal Hematoloji Kongresi, Turkey, 19 - 22 October 2016

142. AllojeneikKökHücreNakli Olan AkutLösemilerdeHazırlıkRejimlerininKarşılaştırılması

ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., et al.

ULUSAL HEMATOLOJİ 2016, Turkey, 18 - 22 October 2016, (Summary Text)

143. AllojeneikKökHücreNakliHastalarımızdaGelişenKataterTrombozları

ATİLLA E., YALÇINER M., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., et al.

ULUSAL HEMATOLOJİ 2016, Turkey, 18 - 22 October 2016, (Summary Text)

144. ALLOJENEİK KÖK HÜCRE NAKLİ YAPILANHASTALARDA PERİTRANSPLANT ALBUMİN DÜŞÜŞÜİLE GVHD İLİŞKİSİ

MERTER M., Şah F. T., ŞAHİN U., YALÇINER M., Kocabay H. E., CİVRİZ BOZDAĞ S., et al.

42. Ulusal Hematoloji Kongresi, Turkey, 19 - 22 October 2016

145. ALLOJENEİK KÖK HÜCRE NAKLİ OLAN AKUTLÖSEMİLERDE HAZIRLIK REJİMLERİNİNKARŞILAŞTIRILMASI

GÜLÖKSÜZ G. A., ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPRAK S. K., et al.

42. Ulusal Hematoloji Kongresi, Turkey, 19 - 22 October 2016

146. PERİFERİK T HÜCRELİ LENFOMALARDA OTOLOGHEMATOPOETİK KÖK HÜCRE TRANSPLANTASYONU TEK MERKEZ DENEYİMİ

ŞAHİN U., MERTER M., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., et al.

42. Ulusal Hematoloji Kongresi, Turkey, 19 - 22 October 2016

147. Approach to Hairy Cell Leukemia HCL 31 years of Experience

KIRCALI E., ATACA ATİLLA P., ATİLLA E., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

EHA 2016, 9 - 12 June 2016, (Summary Text)

148. Age as a dicision factor for doing autuologous stem cell transplantation in fit patients with myeloma and lymphoma ASCO Annual Meeting J Clin Oncol 34 2016 suppl abstr e 19001

İLHAN O., ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.

ASCO, 3 - 07 June 2016

149. Age as a decision factor for doing autologous stem cell transplantation in fit patients with myeloma and lymphoma Subcategory

İLHAN O., ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.

ASCO 2016, ABD, 3 - 07 June 2016, (Summary Text)

150. Age as a decision factor for doing autuologous stem cell transplantation in fit patients with myeloma and lymphoma

İLHAN O., ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.

2016 ASCO Annual Meeting., 3 - 07 June 2016, (Summary Text)

151. Are Age and JAK2V617F Mutation Related to Trombosis in Chronic Myeloproliferative Diseases

ATİLLA E., ATACA ATİLLA P., TOPRAK S. K., KAYGUSUZ G., KUZU I., CİVRİZ BOZDAĞ S., et al.

24th Biennial International Congress on Thrombosis, 4 - 07 May 2016, (Summary Text)

152. Age as a decision factor for doing autologous stem cell transplantation in fit patients with myeloma and lymphoma.

Ilhan O., Atilla E., Ataca P., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 3 - 07 June 2016, vol.34, (Summary Text)

153. Age as a dicision factor for doing autuologous stem cell transplantation in fit patients with myeloma and lymphoma

İLHAN O., ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., et al.

ASCO, 3 - 07 June 2016, (Summary Text)

154. PAROKSİSMAL NOKTÜRNAL HEMOGLOBİNÜRİHASTALARINDA ALLOJENEİK HEMATOPOETİK KÖKHÜCRE NAKLİ TEK MERKEZ DENEYİMİ

NARLI ÖZDEMİR Z., TOPRAK S. K., TOPÇUOĞLU P., ŞAHİN U., GÜNDÜZ M., ATİLLA E., et al.

9.Ulusal Kemik İliği Transplantasyonu ve Kök Hücre Tedavileri Kongresi, Turkey, 3 - 05 March 2016

155. AKTİF HASTALIKLI AKUT LÖSEMİDE ATG VEHAZIRLIK REJİMİ İLE ALLOJENİK NAKİL SONRASICMV REAKTİVASYONUNUN PROGNOZA ETKİSİ

GÜNDÜZ M., ŞAHİN U., MERTER M., NARLI ÖZDEMİR Z., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

9.Ulusal Kemik İliği Transplantasyonu ve Kök Hücre Tedavileri Kongresi, Turkey, 3 - 05 March 2016

156. HAİRY CELL LÖSEMİ HCL VAKALARIMIZ TEKMERKEZ DENEYİMİ

Kırcalı E., ATACA P., ATİLLA E., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

41.Ulusal Hematoloji Kongresi, Turkey, 21 - 24 October 2015

157. Clinical Allogeneic Transplantation Acute and Chronic GVHD Immune Reconstitution

GÜRMAN G., ATACA P., ATİLLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.

57th ASH Annual Meeting & Exposition, 5 - 08 December 2015

158. Positive Impact of Chronic Graft-Versus Host Disease on Survival in 928 Allogeneic Hematopoietic Stem Cell Transplant Recipients

GÜRMAN G., Ataca P., Atilla E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.

57th Annual Meeting of the American-Society-of-Hematology, Florida, United States Of America, 5 - 08 December 2015, vol.126, (Summary Text)

159. Comparison of Two Different Doses of Corticosteroid Premedication for Antithymocyte Globulin in Allogeneic Hematopoietic Stem Cell Transplantation

Merter M., Atilla E., Sahin U., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

57th Annual Meeting of the American-Society-of-Hematology, Florida, United States Of America, 5 - 08 December 2015, vol.126, (Summary Text)

160. Is Initial CD3+T Cell Dose in Donor Lymphocyte Infusion for Relapsed Hematological Malignancies a Prognostic Determinant?

Atilla E., Ataca P., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

57th Annual Meeting of the American-Society-of-Hematology, Florida, United States Of America, 5 - 08 December 2015, vol.126, (Summary Text)

161. Allojeneik Hematopoietik Kök Hücre Nakli AHKHN Hastalarında Gelişen Üst ve Alt Solunum Yolları Viral Enfeksiyonları

ATİLLA E., ATACA P., ŞAHİN D., DOLAPÇI G. İ., TEKELİ F. A., CİVRİZ BOZDAĞ S., et al.

Febril Nötropeni Simpozyumu, Turkey, 28 - 30 November 2015, (Summary Text)

162. Ph Negatif ALL Hastalarında Allojenik Kök Hücre Nakli Öncesi Tedavilerin Klinik Seyir ile İlişkisi

NARLI ÖZDEMİR Z., EKİN K., ATACA P., ATİLLA E., TOPÇUOĞLU P., CİVRİZ BOZDAĞ S., et al.

41. Ulusal Hematoloji Kongresi, Turkey, 21 - 24 October 2015

163. allojeneik hematopoietik kök hücre naklinde iki farklı antitimosit globulin premedikasyon protokolünün karşılaştırılması

MERTER M., ATİLLA E., ŞAHİN U., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

ulusal hematoloji kongresi 2015, Turkey, 21 - 24 October 2015

164. allojeneik hematopoietik kök hücre nakli yapılan hastalarda anti HLA antikorları ile engrafman yetmezliği ilişkisi tek merkez deneyimi

MERTER M., ŞAHİN U., ataşağaoğlu b., TUTKAK H., TOPRAK S. K., YÜKSEL M., et al.

41. Ulusal Hematoloji Kongresi, Turkey, 21 - 24 October 2015, (Summary Text)

165. HODGKİN HL VE HODGKİNDIŞI LENFOMALI HDL HASTALARDA TEDAVİ SONRASI GEÇ DÖNEMDEYÜKSEK HEMATOKRİT DEĞERLERİ HL İLEERİTROSİTOZ ARASINDA İLİŞKİ Mİ VAR

Ateşağaoğlu B., ATACA P., Tuncay G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.

41. Ulusal Hematoloji Kongresi, Turkey, 21 - 24 October 2015

166. ALLOJENEİK HEMATOPOİETİK KÖK HÜCRENAKLİNDE İKİ FARKLI ANTİTİMOSİTGLOBULİN PREMEDİKASYON PROTOKOLÜNÜNKARŞILAŞTIRILMASI

MERTER M., ŞAHİN U., Ateşağaoğlu B., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., et al.

41.Ulusal Hematoloji Kongresi, Turkey, 21 - 24 October 2015

167. Allojeneik Hematopoietik Kök Hücre Nakli Yapılan Hastalarda Anti HLA Antikorları ile Engrafman Yetmezliği İlişkisi: Tek Merkez Deneyimi

MERTER M., ŞAHİN U., ATEŞAĞAOĞLU B., TUTKAK H., TOPRAK S. K., YÜKSEL M., et al.

41. Ulusal Hematoloji Kongresi, Antalya, Turkey, 21 - 24 October 2015, (Summary Text)

168. 928 ALLOJENEİK KÖK HÜCRE TRANSPLANTASYONHASTASINDA KRONİK GRAFT VERSUS HOSTHASTALIĞININ GENEL SAĞKALIM ÜZERİNE ETKİSİ

ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., DEMİRER T., et al.

41. Ulusal Hematoloji Kongresi, Turkey, 21 - 24 October 2015, (Summary Text)

169. ALLOJENEİK KÖK HÜCRE TRANSPLANTASYONHASTASINDA KRONİK GRAFT VERSUS HOSTHASTALIĞININ GENEL SAĞKALIM ÜZERİNE ETKİSİ

ATİLLA E., ATACA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., DEMİRER T., et al.

41. Ulusal Hematoloji Kongresi, Turkey, 21 - 24 October 2015

170. PH NEGATİF ALL HASTALARINDA ALLOJENİK KÖKHÜCRE NAKLİ ÖNCESİ TEDAVİLERİN KLİNİK SEYİRİLE İLİŞKİSİ

Özdemir Z. N., Kırcalı E., ATACA P., ATİLLA E., TOPÇUOĞLU P., CİVRİZ BOZDAĞ S., et al.

41.Ulusal Hematoloji Kongresi, Turkey, 21 - 24 October 2015

171. ALLOJENEİK HEMATOPOİETİK KÖK HÜCRE NAKLİ YAPILAN HASTALARDA ANTİ HLA ANTİKORLARI İLE ENGRAFMAN YETMEZLİĞİ İLİŞKİSİ TEK MERKEZ DENEYİMİ

MERTER M., ŞAHİN U., ateşağaoğlu b., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., et al.

41.Ulusal Hematoloji Kongresi, Turkey, 21 - 23 October 2015, (Summary Text)

172. Allojeneik Hematopoietik Kök Hücre Naklinde İki Farklı Antitimosit Globulin Premedikasyon Protokolünün Karşılaştırılması

MERTER M., ATİLLA E., ŞAHİN U., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., et al.

41. Ulusal Hematoloji Kongresi, Antalya, Turkey, 21 - 24 October 2015, pp.71-72, (Summary Text)

173. Allagenic stemcell transplantation results in our myelodysplastic syndrome MDS patient

GÜRMAN G., ATACA P., AYDIN T., ATİLLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

ASCO -2015, 29 - 02 May 2015

174. Extramedullary Relapse of Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation Allo HSCT A Single Center Experience 41st Annual Meeting of the European Society for Blood and

MERTER M., uğur ş., gündüz m., ATİLLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

(Allo-HSCT): A Single Center Experience. 41st Annual Meeting of the European Society for Blood and Marrow Transplantation, Istanbul, 22-25 Mayıs 2015., 22 - 25 May 2015, (Full Text)

175. Allogeneic Stem Cell Transplantation for Hodgkin and non Hodgkin Lymphoma

ATACA P., ATİLLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., et al.

5th International Congress on Lymphoma Leukemia Myeloma, İstanbul, Turkey, 21-23 May 2015. Turkish Society of Hematology, Proceedings & Abstract Book, abstract # 0109, poster # PS-101 pp 175., 21 - 23 May 2015

176. AUTOLOGOUS STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS 60 YEARS WITH MYELOMA OR LYMPHOMA

ATİLLA E., GÜNDÜZ M., ATACA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., MELTEM K. Y., et al.

5th International Congress on Lymphoma Leukemia Myeloma, İstanbul, Turkey, 21 - 23 May 2015, (Summary Text)

177. Allogeneic stem cell transplantation results in our myelodysplastic syndrome (MDS) patients.

GÜRMAN G., Ataca P., Aydin T., Atilla E., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33, (Summary Text)

178. Autologous Stem Cell Transplantation in Elderly Patients with Myeloma or Lymphoma

ATİLLA E., MEHMET G., ATACA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.

Best of ASBMT Tandem Meetings, Poster Presentation, Turkey, 27 - 28 March 2015

179. THE RELAPSE IN Acute leukemıa after the allogeneıc hematopoetıc stem cell transplantatıon: no approaches have been superıor yet

TOPÇUOĞLU P., GÜNDÜZ M., ÖZEN M., ATİLLA E., ATACA P., CİVRİZ BOZDAĞ S., et al.

41st The European Society for Blood and Marrow Transplantation, 22 - 25 March 2015, (Summary Text)

180. DIFFERENT DOSES OF ATG IN THE CONDITIONING REGIMEN FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

PEKCAN G., ATEŞAĞAOĞLU B., MERTER M., TOPÇUOĞLU P., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

41.EBMT MEETING, 24 - 26 March 2015

181. Autologus stem cell transplantation in elderly patients with myeloma and lymphoma single center experience

GÜNDÜZ M., ATİLLA E., ATACA P., PEKCAN G., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

41.EBMT KONGRESİ, 24 - 26 March 2015

182. ımpact pf pretransplant serum ferritinon outcomes of allogeenic hematopoeitic stem cell transplantationfor acute leukemia

ŞAHİN U., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.

41.ebmt meeting, 22 - 25 March 2015

183. THE RELAPSE IN ACUTE LEUKEMIA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION NO APPROACHES HAVE BEEN SUPERIOR YET

TOPÇUOĞLU P., GÜNDÜZ M., ÖZEN M., ATİLLA E., ATACA P., CİVRİZ BOZDAĞ S., et al.

41.EBMT MEETING, 24 - 26 March 2015

184. Upper and Lower Respiratory Tract Infections by Respiratory Viruses by Respiratory Viruses in Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplantation Single Center Experience

ŞAHİN D., ATİLLA E., CİVRİZ BOZDAĞ S., ATACA P., TOPRAK S. K., TOPÇUOĞLU P., et al.

41th EBMT Meeting, 22 - 25 March 2015, (Summary Text)

185. Different Doses of Anti Thymocyte Globulin ATG in the Conditioning Regimen for Allogeneic Hematopoetic Stem Cell Transplantation 22 25 March 2015 Bone Marrow Transplant 2015 50 S1 S228

GÜLTEKİN P., ATEŞAĞAOĞLU B., MERTER M., TOPÇUOĞLU P., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

41st Annual Meeting of the European Society for Blood and Marrow Transplantation Istanbul, Turkey, 22 - 25 March 2015, (Summary Text)

186. Prognosis of Acute Leukemia Patients with Active Disease Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Allo HSCT 22 25 March 2015 Bone Marrow Transplant 2015 50 S1 S483

UĞUR Ş., MERTER M., ATAŞAĞAOĞLU B., ERDAL H., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

41st Annual Meeting of the European Society for Blood and Marrow Transplantation Istanbul, Turkey, 22 - 25 March 2015, (Summary Text)

187. Generic Bioequivalent Melphalan Has Similar Efficacy and Toxicity but Lower Cost in the Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation 22 25 March 2015 Bone Marrow Transplant 2015 50 S1 S440

TOPÇUOĞLU P., GÜLTAY D., ÖZTÜRK N., KILIÇ Ö., OKAY M., ERASLAN KARADAĞ Y., et al.

41st Annual Meeting of the European Society for Blood and Marrow Transplantation Istanbul, Turkey, 22 - 25 March 2015, (Summary Text)

188. s it possible to overcome the catastrophic complications of Hematopoietic Stem Cell Transplantation HSCT using Plasma Exchange PE A Single Center s Experience

YÜKSEL M., Gultekin G., Edipoglu E., Bay M., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, 22 - 25 March 2015, (Summary Text)

189. Prognosis of Acute Leukemia Patients with Active Disease Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)

Sahin U., Merter M., Atesagaoglu B., Erdai H., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Turkey, 22 - 25 March 2015, vol.50, (Summary Text)

190. Different Doses of Anti-Thymocyte Globulin (ATG) in the Conditioning Regimen for Allogeneic Hematopoetic Stem Cell Transplantation

Pekcan G., Atesagaoglu B., Merter M., Topcuoglu P., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Turkey, 22 - 25 March 2015, (Summary Text)

191. Do FMS-like Tyrosine Kinase 3 and Nucleophospmin 1 Gene Mutations Really Effect Survival in Acute Myeloid Leukemia ?

Gunduz M., Ataca P., Ozen M., Atilla E., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.

56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica, 6 - 09 December 2014, vol.124, (Summary Text)

192. Clinical Reflection of Immunophenotyping in Paroxysmal Nocturnal Hemoglobinuria: Experience of a Single Center

Sahin U., Merter M., Ataca P., Atilla E., Atesagaoglu B., Pekcan G., et al.

56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica, 6 - 09 December 2014, vol.124, (Summary Text)

193. Treatment Approaches in Acute Leukemia Patients Relapsing Following Allogeneic Hematopoietic Stem Cell Transplantation

TOPÇUOĞLU P., Gunduz M., Ozen M., CİVRİZ BOZDAĞ S., TOPRAK S. K., ARSLAN Ö., et al.

56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica, 6 - 09 December 2014, vol.124, (Summary Text)

194. Fertility in Our Allogeneic Hematopoietic Stem Cell Transplant Patients

TOPÇUOĞLU P., Ataca P., CİVRİZ BOZDAĞ S., TOPRAK S. K., ARSLAN Ö., ÖZCAN M., et al.

56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica, 6 - 09 December 2014, vol.124, (Summary Text)

195. Is the Chronic Myeloproliferative Disease Prognosis Really Different in Geriatric Patients?

İLHAN O., Ataca P., Atilla E., TOPRAK S. K., KAYGUSUZ G., KUZU I., et al.

56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica, 6 - 09 December 2014, vol.124, (Summary Text)

196. Is R-CODOX-M/IVAC Inferior to Other Regimens in Burkitt's Lymphoma: A Single Center Experience

Atilla E., Sahin U., Ataca P., Uslu A., Kircali E., Atesagaoglu B., et al.

56th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Costa Rica, 6 - 09 December 2014, vol.124, (Summary Text)

197. FMS Benzeri Tirozin Kinaz 3 ve Nükleofosmin 1 Gen Mutasyonlarının Akut Myeloid Lösemide Sağkalıma Etkisi

gündüz m., ATACA P., ÖZEN M., akfırat h., ATİLLA E., CİVRİZ BOZDAĞ S., et al.

40. Ulusal Hematoloji Kongresi, Turkey, 22 - 25 October 2014, pp.18-19, (Summary Text)

198. R-CODOX-M/IVAC Burkitt Lenfoma’da Diğer Tedavi Rejimlerinden Gerçekten Üstün Mü? Tek Merkez Deneyimi

ATİLLA E., ŞAHİN U., ATACA P., USLU A., KİRÇALI E., ATEŞAĞAOĞLU B., et al.

40. Ulusal Hematoloji Kongresi, Antalya, Turkey, 22 - 25 October 2014, pp.39-40, (Summary Text)

199. STEM CELL MOBILIZASTION IN ELDERLY MULTIPLE MYELOMA PATIENTS: SINGLE CENTER EXPERIENCE

TOPRAK S. K., CENGİZ SEVAL G., AYYILDIZ E., TOPÇUOĞLU P., ARSLAN Ö., ÖZCAN M., et al.

19th Congress of the European Hematology Association, 12 June 2014, (Full Text)

200. İnşaat sırasında meydana gelebilecek hematolojik infeksiyonların engellenmesi

ÖZEN M., YILMAZ G., ÇOŞKUN B., TOPÇUOĞLU P., ÖZTÜRK B., GÜNDÜZ M., et al.

İnfeksiyon dünyası çalıştayı, Turkey, 20 February - 23 March 2014, (Summary Text)

201. AKRABA DIŞI ALLOJENEİK HEMATOPOETİK HÜCRE NAKLİNDE HLA UYUŞUMUNUN ETKİSİ-TEK MERKEZ DENEYİMİ

CENGİZ SEVAL G., TOPÇUOĞLU P., ÖZEN M., GÜNDÜZ M., ATİLLA E., DALVA K., et al.

8. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 06 March 2014, (Summary Text)

202. OTOLOG HEMATOPOETİK KÖK HÜCRE NAKLİ SONRASINDA GELİŞEN BİR CMV RETİNİT VAKASI

CENGİZ SEVAL G., TOPÇUOĞLU P., İDEMEN C., DEMİRER T.

8. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 06 March 2014, (Summary Text)

203. Management of Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem Cell Transplantation

GÜRMAN G., Atilla E., Ozen M., Kubilay P., Yilmaz G., Gunduz M., et al.

BMT Tandem Meetings, Texas, United States Of America, 26 February - 02 March 2014, vol.20, (Summary Text)

204. Comparison Of Flow Cytometric and Clinical Findings In Patients With Paroxysmal Nocturnal Hemoglobinuria

Demirer T., Baslar S., Uysal V. A., Beksac M., Ozen M., Konuk N., et al.

55th Annual Meeting of the American-Society-of-Hematology, Louisiana, United States Of America, 7 - 10 December 2013, vol.122, (Summary Text)

205. Paroksismal Noktürnal Hemoglobinüride İmmünfenotipleme Çalışmalarının Kliniğe Yansıması: Tek Merkez Deneyimi

ŞAHİN U., MERTER M., ATACA P., ATİLLA E., ATEŞAĞAOĞLU B., PEKCAN G., et al.

40. Ulusal Hematoloji Kongresi, Antalya, Turkey, 22 - 25 October 2013, pp.131, (Summary Text)

206. The impact of histopathological subtype of cutaneous chronic GvHD on alloHSCT outcome: lichenoid versus scleradermoid

SOYDAN E., CENGİZ SEVAL G., ŞANLI H., TOPÇUOĞLU P., UĞUR BİLGİN A., BAKANAY ÖZTÜRK Ş. M., et al.

33nd Annual Meeting of the European Society for Blood and Marrow Transplantation, 25 March 2007, (Full Text)

207. MULTİPL MİYELOMA VE MALİN LENFOMALI HASTALARDA OTOLOG PERİFERİK KÖK HÜCRE TOPLANMASINDA AFEREZ GÜN SAYISI ÖNGÖRÜLEBİLİR Mİ? - ANKARA HESAPLAMA FORMÜLÜ

ARAT M., CENGİZ SEVAL G., SOYDAN E., AYYILDIZ E., TOPÇUOĞLU P., ARSLAN Ö., et al.

32. Ulusal Hematoloji Kongresi, 08 November 2006, (Full Text)

208. Refrakter ve Relaps Akut Myeloblastik Lösemide EMA Kurtarma Rejimi Sonuçlarımız

TOPÇUOĞLU P., CİVRİZ BOZDAĞ S., YÜKSEL M., ARSLAN Ö., GÜRMAN G., DEMİRER T., et al.

XXXII. Ulusal Hematoloji Kongresi, Turkey, 8 - 10 November 2006

209. European experience of allogeneic hematopoietic stem cell transplantation for metastatic renal carcinoma: On behalf of the French ITAC group and the EBMT solid tumour working party

Barkholt L., Bregni M., Remberger M., Blaise D., Peccatori J., Massenkeil G., et al.

32nd Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation, Hawaii, United States Of America, 16 - 20 February 2006, vol.12, pp.21, (Summary Text)

210. Allogeneic haematopoietic cell transplantation in acute myeloblastic laeukemia: Ibni Sina experience (1989-2004)

Ilhan O., Topcuoglu P., Arat M., Soydan E., TOPRAK S. K., YÜKSEL M., et al.

31st Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/21st Meeting of the EBMT-Nurses-Group/4th Meeting of the EBMT-Data-Management-Group, Prague, Czech Republic, 20 - 23 March 2005, vol.35, (Summary Text)

211. The comparison of myeloablative versus reduced intensity conditioning regimen in ABO mismatched allogeneic hematopoietic cell transplantation.

Topcuoglu P., Arat M., Bolukbasi T., Soydan E., Ozer Y., Ozcan M., et al.

46th Annual Meeting of the American-Society-of-Hematology, California, United States Of America, 4 - 07 December 2004, vol.104, (Summary Text)

212. Allogeneic hemapoietic progenitor cell collection using four different cell separators: A retrospective comparative analysis.

Arat M., Arslan O., Soydan E., Ayyildiz E., Dalva K., Tol M., et al.

46th Annual Meeting of the American-Society-of-Hematology, California, United States Of America, 4 - 07 December 2004, vol.104, (Summary Text)

213. Prognostic factors for survival in renal cell cancer patients undergoing allogeneic stem cell transplantation: A report from the EBMT Solid Turnouts Working Party

Bregni M., Peccatori J., Barkholt L., Ringden O., Pedrazzoli P., Martino R., et al.

40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22, (Summary Text) Sustainable Development

214. High-dose thiotepa, melphalan and carboplatin followed by autologous peripheral blood stem cell transplantation in patients with lymphoma - a retrospective evaluation

Demirer T., Soydan E., Fen T., Ilhan O., Ayli M., Arat M., et al.

30th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/20th Meeting of the EBMT-Nurses-Group/3rd Meeting of the EBMT-Data-Management-Group, Barcelona, Spain, 28 - 31 March 2004, vol.33, (Summary Text)

215. Graft-versus-tumor effect following reduced-intensity allogeneic stem cell transplantation in renal cell cancer. On behalf of the EBMT solid tumours working party.

Bregni M., Barkholt L., Peccatori J., Pedrazzoli P., Remberger M., Carminati O., et al.

45th Annual Meeting of the American-Society-of-Hematology, SAN DIEGO, CALIFORNIA, 6 - 09 December 2003, vol.102, (Summary Text) Sustainable Development

216. Comparison of three conditioning regimens used in high-dose therapy of malign lymphomas: CBV-ICE-CTM

Soydan E., Arat M., Topcuoglu P., Demirer T., Arslan O., Ozcan M., et al.

29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, İstanbul, Turkey, 23 - 26 March 2003, vol.31, (Summary Text)

Books 1

1. Future Perspectives for Haploidentical Stem Cell Transplantation

ŞAHİN U., DEMİRER T.

in: Haploidentical Stem Cell Transplantation: An Emerging Treatment Modality, TANER DEMİRER, Editor, Humana Press, CHAM, pp.189-198, 2017

Metrics

Publication

415

Publication (WoS)

212

Publication (Scopus)

171

Citation (WoS)

5547

H-Index (WoS)

Citation (Scopus)

5657

H-Index (Scopus)

Thesis Advisory

Open Access

UN Sustainable Development Goals

Publications & Works